


**CUMULATIVE
SUPPLEMENT 2
February 2026**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

**Cumulative Supplement 2
February 2026**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT	vi
1.3	LEVOTHYROXINE SODIUM	vii
1.4	AVAILABILITY OF THE EDITION.....	viii
1.5	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.6	CUMULATIVE SUPPLEMENT LEGEND.....	x
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

46th EDITION

**CUMULATIVE SUPPLEMENT 2
February 2026**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2025</u>	<u>MAR</u> <u>2026</u>	<u>JUN</u> <u>2026</u>	<u>SEP</u> <u>2026</u>	<u>DEC</u> <u>2026</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	24120 2765 (11.5%)				
MULTISOURCE	21355 (88.5%)				
THERAPEUTICALLY EQUIVALENT	21260 (87.1%)				
NOT THERAPEUTICALLY EQUIVALENT	95 (0.4%)				

EXCEPTIONS ⁴	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	19
NUMBER OF APPLICANTS	1198

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CPOT Change. Potency amount/unit.
CRLD Change. Reference Listed Drug
CHRS Change. Reference Standard
CTEC Change. Therapeutic Equivalence Code.
CTNA Change. Trade Name.
DISC Discontinued. The Rx or OTC listed product is not
being marketed and will appear in the discontinued
section in the next edition.

ABARELIX

POWDER; INTRAMUSCULAR
 PLENAXIS

@	SPECIALITY EUROPEAN	100MG/VIAL	N021320	001	Nov 25, 2003	Jan	CDFR
---	---------------------	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	AA	INGENUS PHARMS LLC	300MG; 50MG; 40MG	A215047	001	Nov 17, 2021	Feb	CAHN
>D>	AA	NOVAST LABS	300MG; 50MG; 40MG	A215047	001	Nov 17, 2021	Feb	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	STRIDES PHARMA INTL	325MG; 5MG	A040655	001	Jan 19, 2006	Jan	DISC
@		325MG; 7.5MG	A040656	001	Jan 19, 2006	Jan	DISC
@		325MG; 10MG	A040355	001	May 31, 2000	Jan	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
 OXYCODONE AND ACETAMINOPHEN

>D>	@	LANNETT CO INC	325MG; 5MG	A207333	001	Sep 25, 2017	Feb	CMFD
>A>	AA		325MG; 5MG	A207333	001	Sep 25, 2017	Feb	CMFD
>D>	@		325MG; 10MG	A207333	002	Sep 25, 2017	Feb	CMFD
>A>	AA		325MG; 10MG	A207333	002	Sep 25, 2017	Feb	CMFD

ACYCLOVIR

TABLET; ORAL
 ACYCLOVIR

@	STRIDES PHARMA INTL	400MG	A074946	001	Nov 19, 1997	Jan	DISC
@		800MG	A074946	002	Nov 19, 1997	Jan	DISC

ADAPALENE

SOLUTION; TOPICAL
 ADAPALENE

AB	WAYLIS THERAP	0.1%	A203981	001	Sep 23, 2016	Jan	CAHN
AB		0.1%	A204593	001	Jan 05, 2016	Jan	CAHN

ALISKIREN HEMIFUMARATE

TABLET; ORAL
 TEKTURNA

AB	+ LXO IRELAND	EQ 150MG BASE	N021985	001	Mar 05, 2007	Jan	CAHN
AB	+!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Jan	CAHN

ALPRAZOLAM

TABLET; ORAL
 ALPRAZOLAM

@	STRIDES PHARMA INTL	0.25MG	A090248	001	Sep 17, 2010	Jan	DISC
@		0.5MG	A090248	002	Sep 17, 2010	Jan	DISC
@		1MG	A090248	003	Sep 17, 2010	Jan	DISC
@		2MG	A090248	004	Sep 17, 2010	Jan	DISC

AMINOCAPROIC ACID

SOLUTION; ORAL
 AMINOCAPROIC ACID

>A>	AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Feb	CAHN
>D>	AA	PHARMOBEDIENT	0.25GM/ML	A214140	001	Jan 26, 2021	Feb	CAHN

TABLET; ORAL
 AMINOCAPROIC ACID

>A>	AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Feb	CAHN
>A>	AB		1GM	A213928	002	Feb 12, 2021	Feb	CAHN
>D>	AB	PHARMOBEDIENT	500MG	A213928	001	Feb 12, 2021	Feb	CAHN
>D>	AB		1GM	A213928	002	Feb 12, 2021	Feb	CAHN

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL
SDAMLO

+	!	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jan CMFD
+	!		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jan CMFD
+	!		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jan CMFD

TABLET;ORAL

AMLODIPINE BESYLATE

>A>	AB	GRAVITI PHARMS	EQ 2.5MG BASE	A201380	003	Feb 17, 2026	Feb NEWA
	AB	TEVA PHARMS INC	EQ 2.5MG BASE	A219686	001	Jan 22, 2026	Jan NEWA
	AB		EQ 5MG BASE	A219686	002	Jan 22, 2026	Jan NEWA
	AB		EQ 10MG BASE	A219686	003	Jan 22, 2026	Jan NEWA

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

	@	LUPIN LTD	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014	Jan DISC
	@		EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014	Jan DISC
	@		EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014	Jan DISC
	@		EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014	Jan DISC
>D>	@	MYLAN	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Feb CMFD
>A>			EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Feb CMFD
	@		EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Jan DISC
>D>	@		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb CMFD
>A>			EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Feb CMFD
	@		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Jan DISC
>D>	@		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb CMFD
>A>			EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Feb CMFD
	@		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Jan DISC
>D>	@		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb CMFD
>A>	!		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Feb CMFD
	@		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Jan DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

>A>	!	WA UNIV SCH MED	37.5mCi-800mCi/10ML (3.75-80mCi/ML)	A204506	002	Feb 13, 2026	Feb NFTG
-----	---	-----------------	-------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

	AB	PADAGIS ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	Jan CHRS	
	AB	!	SUN PHARMA CANADA	EQ 12% BASE	A075883	001	Apr 10, 2003	Jan CHRS
>A>	AB	ZYDUS LIFESCIENCES	EQ 12% BASE	A217815	001	Feb 12, 2026	Feb NEWA	

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Jan CTEC
			AUGMENTIN XR					
	AB	+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Jan CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>A>	@	INGENUS PHARMS LLC	5MG	A213763	001	Aug 24, 2020	Feb CAHN
>A>	@		10MG	A213763	002	Aug 24, 2020	Feb CAHN
>D>	@	NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Feb CAHN
>D>	@		10MG	A213763	002	Aug 24, 2020	Feb CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>A>	@	EUROFARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb CAHN
>A>	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb CAHN
>D>	@	MEDIMETRIKS PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Feb CAHN
>D>	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Feb CAHN

APREPITANT

EMULSION; INTRAVENOUS
 APONVIE

>D>	+	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Feb CFTG
>A>	AB	+	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Feb CFTG
>A>		APREPITANT					
>A>	AB	MYLAN	32MG/4.4ML (7.2MG/ML)	A218851	001	Mar 05, 2026	Feb NFTG

ARIPIPIRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL
 ARIPIPIRAZOLE

>A>	AB	AUROBINDO PHARMA	10MG	A216208	001	Feb 18, 2026	Feb NEWA
>A>	AB		15MG	A216208	002	Feb 18, 2026	Feb NEWA

ARMODAFINIL

TABLET; ORAL
 ARMODAFINIL

AB		COREPHARMA	50MG	A201514	001	Mar 25, 2019	Jan CMFD
AB			150MG	A201514	002	Mar 25, 2019	Jan CMFD
AB			250MG	A201514	003	Mar 25, 2019	Jan CMFD

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
 ARSENIC TRIOXIDE

>A>	AP	INGENUS PHARMS LLC	1MG/ML	A209315	001	Nov 15, 2018	Feb CAHN
>A>		@	2MG/ML	A209315	002	Jan 14, 2021	Feb CAHN
>D>	AP	NOVAST LABS	1MG/ML	A209315	001	Nov 15, 2018	Feb CAHN
>D>		@	2MG/ML	A209315	002	Jan 14, 2021	Feb CAHN

ARTICAINE HYDROCHLORIDE

>D>		SOLUTION/DROPS; OPHTHALMIC						
>D>		CYKLX						
>D>		+	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Feb DISC
>A>		@ +		EQ 8% BASE	N218643	001	Aug 15, 2025	Feb DISC

ATENOLOL

TABLET; ORAL
 ATENOLOL

AB		IPCA LABS LTD	25MG	A077877	001	Dec 27, 2006	Jan CMFD
AB			50MG	A077877	002	Dec 27, 2006	Jan CMFD
AB			100MG	A077877	003	Dec 27, 2006	Jan CMFD

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>A>		@	QUAGEN	0.025MG; 2.5MG	A210571	001	Aug 31, 2018	Feb CAHN
>D>		@	UPSHER SMITH LABS	0.025MG; 2.5MG	A210571	001	Aug 31, 2018	Feb CAHN

AZITHROMYCIN

TABLET; ORAL
 AZITHROMYCIN

>A>		@	CARLSBAD	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb CAHN
>A>	AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb CAHN
>D>		@	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb CAHN
>D>	AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb CAHN

AZTREONAM

INJECTABLE; INJECTION
 AZTREONAM

>D>	AP	HIKMA	1GM/VIAL	A207069	001	Feb 05, 2026	Feb DISC
>A>		@	1GM/VIAL	A207069	001	Feb 05, 2026	Feb DISC
	AP		1GM/VIAL	A207069	001	Feb 05, 2026	Jan NEWA
>D>	AP		2GM/VIAL	A207069	002	Feb 05, 2026	Feb DISC
>A>		@	2GM/VIAL	A207069	002	Feb 05, 2026	Feb DISC
	AP		2GM/VIAL	A207069	002	Feb 05, 2026	Jan NEWA

BACLOFEN

	GRANULES;ORAL						
	LYVISPAAH						
	@ +	STRIDES PHARMA INTL	5MG/PACKET	N215422	001	Nov 22, 2021	Jan CAHN
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jan CAHN
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jan CAHN
	TABLET;ORAL						
	BACLOFEN						
AB		RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jan CHRS

BALSALAZIDE DISODIUM

	CAPSULE;ORAL						
	BALSALAZIDE DISODIUM						
>A>	AB	CARNEGIE	750MG	A219422	001	Apr 03, 2025	Feb CAHN
>D>	AB	PHARMOBEDIENT	750MG	A219422	001	Apr 03, 2025	Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL						
	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
AB	!	SANDOZ	20MG;25MG	A076631	004	Feb 11, 2004	Jan CHRS
		LOTENSIN HCT					
AB	+	VALIDUS PHARMS	20MG;25MG	N020033	003	May 19, 1992	Jan CHRS

BETAMETHASONE DIPROPIONATE

	CREAM;TOPICAL						
	BETAMETHASONE DIPROPIONATE						
AB		AUROBINDO PHARMA LTD	EQ 0.05% BASE	A219348	001	Jan 26, 2026	Jan NEWA

BETAMETHASONE VALERATE

	AEROSOL, FOAM;TOPICAL						
	BETAMETHASONE VALERATE						
>A>	@	INGENUS PHARMS LLC	0.12%	A207144	001	May 24, 2017	Feb CAHN
>D>	@	NOVAST LABS	0.12%	A207144	001	May 24, 2017	Feb CAHN

BETAXOLOL HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	BETAXOLOL HYDROCHLORIDE						
>A>	AT	EUROFARMA	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb CAHN
>D>	AT	MEDIMETRIKS PHARMS	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Feb CAHN

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

	CAPSULE;ORAL						
	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE						
>A>	AB	INGENUS PHARMS LLC	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb CAHN
>D>	AB	NOVAST LABS	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Feb CAHN

BISOPROLOL FUMARATE

	TABLET;ORAL						
	BISOPROLOL FUMARATE						
>A>	AB	MICRO LABS	5MG	A218303	001	Mar 09, 2026	Feb NEWA
>A>	AB		10MG	A218303	002	Mar 09, 2026	Feb NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL						
	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE						
AB		AUROBINDO PHARMA LTD	2.5MG;6.25MG	A217922	001	Jan 21, 2026	Jan NEWA
AB			5MG;6.25MG	A217922	002	Jan 21, 2026	Jan NEWA
AB			10MG;6.25MG	A217922	003	Jan 21, 2026	Jan NEWA

BORTEZOMIB

	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS						
	BORTEZOMIB						
AP		CAPLIN ONE LABS	3.5MG/VIAL	A203654	001	Jul 26, 2022	Jan CAHN

BOSENTAN

	TABLET, FOR SUSPENSION;ORAL						
	BOSENTAN						
>A>	AB	ZYDUS PHARMS	32MG	A213981	001	Feb 17, 2026	Feb NEWA

BRIGATINIB

TABLET; ORAL
ALUNBRIG

+	!	TAKEDA PHARMS USA	90MG	N208772	002	Apr 28, 2017	Jan	CHRS
+			180MG	N208772	003	Oct 02, 2017	Jan	CHRS

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

>A>	AB	GLAND	0.1%	A219219	001	Mar 11, 2026	Feb	NEWA
-----	----	-------	------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE; CARBACHOL

SOLUTION/DROPS; OPHTHALMIC
YUVEZZI

+	!	VISUS	0.1%; 2.75%	N220142	001	Jan 28, 2026	Jan	NEWA
---	---	-------	-------------	---------	-----	--------------	-----	------

BRIVARACETAM

SOLUTION; INTRAVENOUS
BRIVARACETAM

>A>	AP	HAINAN POLY	50MG/5ML (10MG/ML)	A218249	001	Feb 23, 2026	Feb	NFTG			
>A>	AP	MICRO LABS	50MG/5ML (10MG/ML)	A214880	001	Feb 23, 2026	Feb	NFTG			
>A>	AP	MSN	50MG/5ML (10MG/ML)	A214924	001	Feb 23, 2026	Feb	NFTG			
>D>		BRIVIACT									
>D>		+	!	UCB INC		50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb	CFTG
>A>	AP	+	!			50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	Feb	CFTG

SOLUTION; ORAL
BRIVARACETAM

>A>	AA	ALKEM LABS LTD	10MG/ML	A219772	001	Feb 23, 2026	Feb	NEWA			
>A>	AA	INDOCO	10MG/ML	A220385	001	Feb 23, 2026	Feb	NEWA			
>A>	AA	LUPIN	10MG/ML	A220164	001	Feb 23, 2026	Feb	NEWA			
>A>	AA	MSN	10MG/ML	A214922	001	Feb 19, 2026	Feb	NFTG			
>A>	AA	ZHEJIANG POLY PHARM	10MG/ML	A218494	001	Feb 23, 2026	Feb	NEWA			
>D>		BRIVIACT									
>D>		+	!	UCB INC		10MG/ML	N205838	001	May 12, 2016	Feb	CFTG
>A>	AA	+	!			10MG/ML	N205838	001	May 12, 2016	Feb	CFTG

TABLET; ORAL
BRIVARACETAM

>A>	AB	APOTEX	10MG	A214875	001	Feb 23, 2026	Feb	NEWA
>A>	AB		25MG	A214875	002	Feb 23, 2026	Feb	NEWA
>A>	AB		50MG	A214875	003	Feb 23, 2026	Feb	NEWA
>A>	AB		75MG	A214875	004	Feb 23, 2026	Feb	NEWA
>A>	AB		100MG	A214875	005	Feb 23, 2026	Feb	NEWA
	AB	AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Jan	CMFD
	AB		100MG	A214848	002	Jan 06, 2023	Jan	CMFD
>A>	AB	CENTAUR PHARMS PVT	10MG	A220470	001	Feb 23, 2026	Feb	NEWA
>A>	AB		25MG	A220470	002	Feb 23, 2026	Feb	NEWA
>A>	AB		50MG	A220470	003	Feb 23, 2026	Feb	NEWA
>A>	AB		75MG	A220470	004	Feb 23, 2026	Feb	NEWA
>A>	AB		100MG	A220470	005	Feb 23, 2026	Feb	NEWA
	AB	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Jan	CMFD
	AB		25MG	A214748	002	Jun 09, 2022	Jan	CMFD
	AB		50MG	A214748	003	Jun 09, 2022	Jan	CMFD
	AB		75MG	A214748	004	Jun 09, 2022	Jan	CMFD
	AB		100MG	A214748	005	Jun 09, 2022	Jan	CMFD

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
BROMFED-DM

@	+	PHARMOBEDIENT	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Jan	DISC
---	---	---------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDE

SUSPENSION; INHALATION
PULMICORT RESPULES

AN	+	!	ASTRAZENECA	0.25MG/2ML	N020929	001	Aug 08, 2000	Jan	CHRS
AN	+	!		0.5MG/2ML	N020929	002	Aug 08, 2000	Jan	CHRS

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE

>A>	AP	ANTHEA PHARMA	0.25MG/ML	A220427	001	Feb 26, 2026	Feb NEWA
		TABLET; ORAL					
		BUMETANIDE					
	AB	MSN	0.5MG	A215362	001	Feb 05, 2026	Jan NEWA
	AB		1MG	A215362	002	Feb 05, 2026	Jan NEWA
	AB		2MG	A215362	003	Feb 05, 2026	Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

	AB	ASCENT PHARMS INC	EQ 2MG BASE;EQ 0.5MG BASE	A219850	001	Jan 21, 2026	Jan NEWA
	AB		EQ 4MG BASE;EQ 1MG BASE	A219850	002	Jan 21, 2026	Jan NEWA
	AB		EQ 8MG BASE;EQ 2MG BASE	A219850	003	Jan 21, 2026	Jan NEWA
	AB		EQ 12MG BASE;EQ 3MG BASE	A219850	004	Jan 21, 2026	Jan NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HYDROCHLORIDE

>D>	AB	APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Feb CAHN
>D>	AB		100MG	A075584	002	Feb 07, 2000	Feb CAHN
>A>	AB	SENORES PHARMS	75MG	A075584	001	Feb 07, 2000	Feb CAHN
>A>	AB		100MG	A075584	002	Feb 07, 2000	Feb CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPIRONE HYDROCHLORIDE

>D>	AB	MYLAN	7.5MG	A076008	002	Jul 08, 2013	Feb DISC
>A>		@	7.5MG	A076008	002	Jul 08, 2013	Feb DISC

CALCITONIN SALMON

INJECTABLE; INJECTION
CALCITONIN-SALMON

>A>	AP	ZYDUS PHARMS	200 IU/ML	A215864	001	Mar 04, 2026	Feb NEWA
-----	----	--------------	-----------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

>A>	AB	HUMANWELL PURACAP	0.25MCG	A219796	001	Feb 27, 2026	Feb NEWA
>A>	AB		0.5MCG	A219796	002	Feb 27, 2026	Feb NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

	AB	SENORES PHARMS	16MG;12.5MG	A202965	001	Jun 03, 2013	Jan CAHN
	AB		32MG;12.5MG	A202965	002	Jun 03, 2013	Jan CAHN
	AB		32MG;25MG	A202965	003	Jun 03, 2013	Jan CAHN

CAPECITABINE

TABLET; ORAL
CAPECITABINE

	AB	! DR REDDYS	500MG	A204345	002	Dec 04, 2020	Jan CHRS
		XELODA					
		@ + CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Jan DISC
		@ +	500MG	N020896	002	Apr 30, 1998	Jan DISC

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

>A>	AB	INGENUS PHARMS LLC	100MG	A216404	001	Dec 02, 2022	Feb CAHN
>A>	AB		200MG	A216404	002	Dec 02, 2022	Feb CAHN
>A>	AB		400MG	A216404	003	Dec 02, 2022	Feb CAHN
>D>	AB	NOVAST LABS	100MG	A216404	001	Dec 02, 2022	Feb CAHN
>D>	AB		200MG	A216404	002	Dec 02, 2022	Feb CAHN
>D>	AB		400MG	A216404	003	Dec 02, 2022	Feb CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	ALEMBIC	12.5MG; 200MG; 50MG	A 218535	001	Feb 05, 2026	Jan	NEWA
AB		18.75MG; 200MG; 75MG	A 218535	002	Feb 05, 2026	Jan	NEWA
AB		25MG; 200MG; 100MG	A 218535	003	Feb 05, 2026	Jan	NEWA
AB		31.25MG; 200MG; 125MG	A 218535	004	Feb 05, 2026	Jan	NEWA
AB		37.5MG; 200MG; 150MG	A 218535	005	Feb 05, 2026	Jan	NEWA
AB		50MG; 200MG; 200MG	A 218535	006	Feb 05, 2026	Jan	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

>D>	AB	SUN PHARM INDS	25MG; 100MG	A 077828	001	Aug 23, 2007	Feb	DISC
>A>		@	25MG; 100MG	A 077828	001	Aug 23, 2007	Feb	DISC
>D>	AB		50MG; 200MG	A 077828	002	Aug 23, 2007	Feb	DISC
>A>		@	50MG; 200MG	A 077828	002	Aug 23, 2007	Feb	DISC

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

>D>	AP	NOVAST LABS	50MG/5ML (10MG/ML)	A 208487	001	Apr 26, 2017	Feb	DISC
>A>		@	50MG/5ML (10MG/ML)	A 208487	001	Apr 26, 2017	Feb	DISC
>D>	AP		150MG/15ML (10MG/ML)	A 208487	002	Apr 26, 2017	Feb	DISC
>A>		@	150MG/15ML (10MG/ML)	A 208487	002	Apr 26, 2017	Feb	DISC
>D>	AP		450MG/45ML (10MG/ML)	A 208487	003	Apr 26, 2017	Feb	DISC
>A>		@	450MG/45ML (10MG/ML)	A 208487	003	Apr 26, 2017	Feb	DISC
>D>	AP		600MG/60ML (10MG/ML)	A 208487	004	Apr 26, 2017	Feb	DISC
>A>		@	600MG/60ML (10MG/ML)	A 208487	004	Apr 26, 2017	Feb	DISC
	AP	QILU PHARM HAINAN	50MG/5ML (10MG/ML)	A 219999	001	Feb 04, 2026	Jan	NEWA
	AP		150MG/15ML (10MG/ML)	A 219999	002	Feb 04, 2026	Jan	NEWA
	AP		450MG/45ML (10MG/ML)	A 219999	003	Feb 04, 2026	Jan	NEWA
	AP		600MG/60ML (10MG/ML)	A 219999	004	Feb 04, 2026	Jan	NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

CARIPRAZINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD
 @
 @

VRAYLAR

+! ABBVIE
 +
 +

EQ 1.5MG BASE	A 213982	001	Dec 16, 2025	Jan	DISC
EQ 3MG BASE	A 213982	002	Dec 16, 2025	Jan	DISC
EQ 6MG BASE	A 213982	003	Dec 16, 2025	Jan	DISC
EQ 1.5MG BASE	N 204370	001	Sep 17, 2015	Jan	CTEC
EQ 3MG BASE	N 204370	002	Sep 17, 2015	Jan	CTEC
EQ 6MG BASE	N 204370	004	Sep 17, 2015	Jan	CTEC

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>A>	AA	INGENUS PHARMS LLC	350MG	A 040823	001	Oct 22, 2008	Feb	CAHN
>D>	AA	NOVAST LABS	350MG	A 040823	001	Oct 22, 2008	Feb	CAHN

CARVEDILOL

TABLET; ORAL

CARVEDILOL

>D>	AB	LUPIN	3.125MG	A 078217	001	Sep 05, 2007	Feb	DISC
>A>		@	3.125MG	A 078217	001	Sep 05, 2007	Feb	DISC
>D>	AB		6.25MG	A 078217	002	Sep 05, 2007	Feb	DISC
>A>		@	6.25MG	A 078217	002	Sep 05, 2007	Feb	DISC
>D>	AB		12.5MG	A 078217	003	Sep 05, 2007	Feb	DISC
>A>		@	12.5MG	A 078217	003	Sep 05, 2007	Feb	DISC
>D>	AB		25MG	A 078217	004	Sep 05, 2007	Feb	DISC
>A>		@	25MG	A 078217	004	Sep 05, 2007	Feb	DISC

CEFAZOLIN SODIUM

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

>A>		+! HQ SPCLT PHARMA	EQ 3GM BASE/VIAL	N 211413	002	Mar 08, 2024	Feb	NEWA
-----	--	--------------------	------------------	----------	-----	--------------	-----	------

CEFIXIME

TABLET; ORAL
CEFIXIME

! FDC LTD 400MG A206358 001 Dec 17, 2024 Jan CMFD

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS
CEFTAROLINE FOSAMIL

AP APOTEX 400MG/VIAL A208075 001 Sep 21, 2021 Jan CMFD
AP 600MG/VIAL A208075 002 Sep 21, 2021 Jan CMFD

TEFLARO

AP +! ABBVIE 400MG/VIAL N200327 001 Oct 29, 2010 Jan CTEC
AP +! 600MG/VIAL N200327 002 Oct 29, 2010 Jan CTEC

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL
CETIRIZINE HYDROCHLORIDE

>A> AA RUBICON RESEARCH 5MG/5ML A220335 001 Feb 25, 2026 Feb NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
CEVIMELINE HYDROCHLORIDE

>A> AB ZYDUS LIFESCIENCES 30MG A220267 001 Mar 11, 2026 Feb NEWA

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM

>A> AB + BAUSCH 5MG A085461 001 Feb CAHN
>A> AB + 10MG A085472 001 Feb CAHN
>D> AB + VALEANT PHARM INTL 5MG A085461 001 Feb CAHN
>D> AB + 10MG A085472 001 Feb CAHN

CHLOROTHIAZIDE

SUSPENSION; ORAL
DIURIL

@ + SALIX PHARMS 250MG/5ML N011870 001 Jan DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HYDROCHLORIDE

AP MSN 25MG/ML A216092 001 Jan 26, 2026 Jan NEWA

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB ZAMEER PHARMS 10MG A212630 001 Nov 29, 2021 Jan CAHN
AB 25MG A212630 002 Nov 29, 2021 Jan CAHN
AB 50MG A212630 003 Nov 29, 2021 Jan CAHN
AB 100MG A212630 004 Nov 29, 2021 Jan CAHN
AB 200MG A212630 005 Nov 29, 2021 Jan CAHN

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA SENORES PHARMS 500MG A210961 001 Jan 22, 2024 Jan CAHN

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

>A> AB MICRO LABS EQ 4GM RESIN/PACKET A219318 001 Mar 05, 2026 Feb NEWA
AB PHARMOBEDIANT EQ 4GM RESIN/PACKET A209597 001 Mar 09, 2021 Jan CAHN
AB EQ 4GM RESIN/SCOOPFUL A209597 002 Mar 09, 2021 Jan CAHN

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE

>D> AP RK PHARMA EQ 0.004MG CHROMIUM/ML A218538 001 Nov 18, 2024 Feb CAHN
>A> AP SOMERSET THERAPS LLC EQ 0.004MG CHROMIUM/ML A218538 001 Nov 18, 2024 Feb CAHN

CICLOPIROX

CREAM;TOPICAL

LOPROX

>A>	AB	+	EUROFARMA	0.77%	N018748	001	Dec 30, 1982	Feb	CAHN
>D>	AB	+	MEDIMETRIKS PHARMS	0.77%	N018748	001	Dec 30, 1982	Feb	CAHN

SUSPENSION;TOPICAL

LOPROX

>A>	AB	+	EUROFARMA	0.77%	N019824	001	Dec 30, 1988	Feb	CAHN
>D>	AB	+	MEDIMETRIKS PHARMS	0.77%	N019824	001	Dec 30, 1988	Feb	CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>D>	AB		HETERO LABS LTD V	EQ 30MG BASE	A209403	001	Oct 07, 2020	Feb	DISC
>A>		@		EQ 30MG BASE	A209403	001	Oct 07, 2020	Feb	DISC
>D>	AB			EQ 60MG BASE	A209403	002	Oct 07, 2020	Feb	DISC
>A>		@		EQ 60MG BASE	A209403	002	Oct 07, 2020	Feb	DISC
>D>	AB			EQ 90MG BASE	A209403	003	Oct 07, 2020	Feb	DISC
>A>		@		EQ 90MG BASE	A209403	003	Oct 07, 2020	Feb	DISC
>D>		@	STEVENS J	30MG	A204364	001	Dec 02, 2021	Feb	CPOT
>A>		@		EQ 30MG BASE	A204364	001	Dec 02, 2021	Feb	CPOT
>D>		@		60MG	A204364	002	Dec 02, 2021	Feb	CPOT
>A>		@		EQ 60MG BASE	A204364	002	Dec 02, 2021	Feb	CPOT
>D>		@		90MG	A204364	003	Dec 02, 2021	Feb	CPOT
>A>		@		EQ 90MG BASE	A204364	003	Dec 02, 2021	Feb	CPOT

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

>D>	AP		HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	DISC
>A>		@		EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	DISC
			CISATRACURIUM BESYLATE PRESERVATIVE FREE						
>D>	AP		HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Feb	DISC
>A>		@		EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Feb	DISC
>D>	AP			EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Feb	DISC
>A>		@		EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Feb	DISC

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB		AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb	DISC
>A>		@		EQ 10MG BASE	A077289	001	Nov 30, 2006	Feb	DISC
>D>	AB			EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb	DISC
>A>		@		EQ 20MG BASE	A077289	002	Nov 30, 2006	Feb	DISC
>D>	AB			EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb	DISC
>A>		@		EQ 40MG BASE	A077289	003	Nov 30, 2006	Feb	DISC

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	AB1		QUAGEN	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb	CAHN
>A>	AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Feb	CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

>A>		@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb	CAHN
>D>		@	NOVAST LABS	EQ 1% BASE	A064108	001	Sep 27, 1996	Feb	CAHN

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB			CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997	Jan	CMFD
AB				1MG	A074925	002	Sep 30, 1997	Jan	CMFD
AB				2MG	A074925	003	Sep 30, 1997	Jan	CMFD

CLONIDINE

SYSTEM;TRANSDERMAL

CLONIDINE

>A>		@	DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Feb	CAHN
>A>		@		0.2MG/24HR	A076157	002	Aug 18, 2009	Feb	CAHN
>A>		@		0.3MG/24HR	A076157	003	Aug 18, 2009	Feb	CAHN
>D>		@	INGENUS PHARMS LLC	0.1MG/24HR	A076157	001	Aug 18, 2009	Feb	CAHN

	SYSTEM; TRANSDERMAL							
	CLONIDINE							
>D>	@	0.2MG/24HR	A076157	002	Aug 18, 2009	Feb	CAHN	
>D>	@	0.3MG/24HR	A076157	003	Aug 18, 2009	Feb	CAHN	
>A>	<u>COBICISTAT; DARUNAVIR ETHANOLATE</u>							
>A>	TABLET, FOR SUSPENSION; ORAL							
>A>	PREZCOBIX PED							
>A>	+!	JANSSEN PRODS	90MG; EQ 600MG BASE	N220092	001	Feb 27, 2026	Feb	NEWA
	<u>COLCHICINE</u>							
	CAPSULE; ORAL							
	COLCHICINE							
>A>	AB	MICRO LABS	0.6MG	A212880	001	Feb 17, 2026	Feb	NEWA
	TABLET; ORAL							
	COLCHICINE							
>A>	AB	MACLEODS PHARMS LTD	0.6MG	A210633	001	Feb 13, 2026	Feb	NEWA
	<u>COPPER HISTIDINATE</u>							
	POWDER; SUBCUTANEOUS							
	ZYCUBO							
	+!	SENTYNL THERAPS INC	2.9MG/VIAL	N211241	001	Jan 12, 2026	Jan	NEWA
	<u>CUPRIC CHLORIDE</u>							
	INJECTABLE; INJECTION							
	CUPRIC CHLORIDE							
AP		AMNEAL	EQ 0.4MG COPPER/ML	A217287	001	Jan 26, 2026	Jan	NEWA
	<u>CYCLOPHOSPHAMIDE</u>							
	INJECTABLE; INJECTION							
	CYCLOPHOSPHAMIDE							
	@	HAINAN POLY	500MG/VIAL	A218632	001	Dec 26, 2024	Jan	DISC
	@		1GM/VIAL	A218632	002	Dec 26, 2024	Jan	DISC
	@		2GM/VIAL	A218632	003	Dec 26, 2024	Jan	DISC
	<u>CYCLOSPORINE</u>							
	EMULSION; OPHTHALMIC							
	CYCLOSPORINE							
AB		TWI PHARMS	0.05%	A209064	001	Jan 21, 2026	Jan	NEWA
	<u>CYPROHEPTADINE HYDROCHLORIDE</u>							
	SYRUP; ORAL							
	CYPROHEPTADINE HYDROCHLORIDE							
AA		ST JOHN PHARM	2MG/5ML	A209108	001	Oct 16, 2018	Jan	CAHN
	TABLET; ORAL							
	CYPROHEPTADINE HYDROCHLORIDE							
>A>	AA	INGENUS PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Feb	CAHN
>D>	AA	NOVAST LABS	4MG	A205087	001	Sep 23, 2015	Feb	CAHN
	<u>DALBAVANCIN HYDROCHLORIDE</u>							
	POWDER; INTRAVENOUS							
	DALBAVANCIN HYDROCHLORIDE							
>A>	AP	LONG GROVE PHARMS	EQ 500MG BASE/VIAL	A218602	001	Feb 26, 2026	Feb	NEWA
	<u>DAPSONE</u>							
	TABLET; ORAL							
	DAPSONE							
>A>	AB	ZYDUS LIFESCIENCES	25MG	A220103	001	Feb 26, 2026	Feb	NEWA
>A>	AB		100MG	A220103	002	Feb 26, 2026	Feb	NEWA
	<u>DAPTOMYCIN</u>							
	POWDER; INTRAVENOUS							
	DAPTOMYCIN							
	@	HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019	Jan	DISC
	<u>DASIGLUCAGON HYDROCHLORIDE</u>							
	SOLUTION; SUBCUTANEOUS							
	ZEGALOGUE							
>D>	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb	DISC
>A>	@ +		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Feb	DISC

SOLUTION;SUBCUTANEOUS
 >D> ZEGALOGUE (AUTOINJECTOR)
 >D> +! ZEALAND PHARMA EQ 0.6MG BASE/0.6ML (EQ 0.6MG N214231 002 Mar 22, 2021 Feb DISC
 BASE/0.6ML)
 >A> @ + EQ 0.6MG BASE/0.6ML (EQ 0.6MG N214231 002 Mar 22, 2021 Feb DISC
 BASE/0.6ML)

DECITABINE

INJECTABLE;INTRAVENOUS
 DECITABINE
 >D> AP NOVAST LABS 50MG/VIAL A210984 001 Sep 16, 2019 Feb DISC
 >A> @ 50MG/VIAL A210984 001 Sep 16, 2019 Feb DISC

DEFLAZACORT

SUSPENSION;ORAL
 DEFLAZACORT
 AB SUN PHARM INDS INC 22.75MG/ML A219930 001 Jan 27, 2026 Jan NEWA

DEHYDRATED ALCOHOL

SOLUTION;INTRA-ARTERIAL
 ABLYSINOL
 @ + BPI LABS 99% (1ML) N207987 001 Jun 21, 2018 Jan CAIN
 AP +! 99% (5ML) N207987 002 Jun 21, 2018 Jan CAIN
 DEHYDRATED ALCOHOL
 AP ACCORD HLTHCARE 99% (5ML) A217845 001 Jun 23, 2025 Jan CAIN
 AP BRECKENRIDGE 99% (5ML) A219444 001 Jun 23, 2025 Jan CAIN
 AP INGENUS PHARMS LLC 99% (5ML) A219569 001 Jul 09, 2025 Jan CAIN
 AP XGEN PHARMS 99% (5ML) A219400 001 Jun 23, 2025 Jan CAIN
 SOLUTION;INTRAVENOUS
 DEHYDRATED ALCOHOL
 +! ROYAL PHARMS 98% (5ML) N214988 001 Oct 23, 2025 Jan CAIN

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
 DESIPRAMINE HYDROCHLORIDE
 @ HERITAGE 10MG A207433 001 May 05, 2016 Jan DISC
 @ 25MG A207433 002 May 05, 2016 Jan DISC
 @ 50MG A207433 003 May 05, 2016 Jan DISC
 @ 75MG A207433 004 May 05, 2016 Jan DISC
 @ 100MG A207433 005 May 05, 2016 Jan DISC
 @ 150MG A207433 006 May 05, 2016 Jan DISC
 >A> AB INGENUS PHARMS LLC 10MG A204963 001 Dec 26, 2017 Feb CAHN
 >A> AB 25MG A204963 002 Dec 26, 2017 Feb CAHN
 >A> AB 50MG A204963 003 Dec 26, 2017 Feb CAHN
 >A> AB 75MG A204963 004 Dec 26, 2017 Feb CAHN
 >A> AB 100MG A204963 005 Dec 26, 2017 Feb CAHN
 >A> AB 150MG A204963 006 Dec 26, 2017 Feb CAHN
 >D> AB NOVAST LABS 10MG A204963 001 Dec 26, 2017 Feb CAHN
 >D> AB 25MG A204963 002 Dec 26, 2017 Feb CAHN
 >D> AB 50MG A204963 003 Dec 26, 2017 Feb CAHN
 >D> AB 75MG A204963 004 Dec 26, 2017 Feb CAHN
 >D> AB 100MG A204963 005 Dec 26, 2017 Feb CAHN
 >D> AB 150MG A204963 006 Dec 26, 2017 Feb CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION
 DESMOPRESSIN ACETATE
 >A> AP CAPLIN 0.004MG/ML A219981 001 Feb 27, 2026 Feb NEWA
 >A> SOLUTION;ORAL
 >A> DESMODA
 >A> +! ETON 0.05MG/ML N219873 001 Feb 25, 2026 Feb NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
 DESVENLAFAXINE SUCCINATE
 >A> AB YICHANG HUMANWELL EQ 25MG BASE A220460 001 Mar 10, 2026 Feb NEWA
 >A> AB EQ 50MG BASE A220460 002 Mar 10, 2026 Feb NEWA
 >A> AB EQ 100MG BASE A220460 003 Mar 10, 2026 Feb NEWA

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

+! HIKMA 1MG/ML A088252 001 Sep 01, 1983 Jan CRLD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

@ CAPLIN EQ 0.1% PHOSPHATE A088771 001 Jan 16, 1985 Jan CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

+ BIOXCEL EQ 0.18MG BASE N215390 002 Apr 05, 2022 Jan CHRS

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP CAPLIN EQ 200MCG BASE/2ML (EQ 100MCG A091465 001 Jun 14, 2016 Jan CAHN

>A> AP DR REDDYS EQ 200MCG BASE/50ML (EQ 4MCG A220315 001 Feb 25, 2026 Feb NEWA

>A> AP EQ 400MCG BASE/100ML (EQ 4MCG A220315 002 Feb 25, 2026 Feb NEWA

>A> AP KNACK EQ 200MCG BASE/2ML (EQ 100MCG A218675 001 Mar 09, 2026 Feb NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

@ STRIDES PHARMA INTL 5MG A205673 001 Oct 31, 2017 Jan DISC

@ 10MG A205673 002 Oct 31, 2017 Jan DISC

@ 15MG A205673 003 Oct 31, 2017 Jan DISC

DIAZEPAM

TABLET;ORAL

DIAZEPAM

@ STRIDES PHARMA INTL 2MG A077749 001 Mar 31, 2006 Jan DISC

@ 5MG A077749 002 Mar 31, 2006 Jan DISC

@ 10MG A077749 003 Mar 31, 2006 Jan DISC

DICLOFENAC POTASSIUM

CAPSULE;ORAL

ZIPSOR

>D> AB +! ASIO HOLDINGS 25MG N022202 001 Jun 16, 2009 Feb CAHN

>A> AB +! ASSERTIO SPECLTY 25MG N022202 001 Jun 16, 2009 Feb CAHN

FOR SOLUTION;ORAL

CAMBIA

>D> AB +! ASIO HOLDINGS 50MG N022165 001 Jun 17, 2009 Feb CAHN

>A> AB +! ASSERTIO SPECLTY 50MG N022165 001 Jun 17, 2009 Feb CAHN

TABLET;ORAL

DICLOFENAC POTASSIUM

>A> AB INGENUS PHARMS LLC 50MG A215585 001 Oct 08, 2021 Feb CAHN

>D> AB NOVAST LABS 50MG A215585 001 Oct 08, 2021 Feb CAHN

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

>A> AB INGENUS PHARMS LLC 100MG A216275 001 Sep 23, 2022 Feb CAHN

>D> AB NOVAST LABS 100MG A216275 001 Sep 23, 2022 Feb CAHN

>A> DIFAMILAST

>A> OINTMENT;TOPICAL

>A> ADQUEY

>A> +! ACROTECH BIOPHARMA 1% N219474 001 Feb 12, 2026 Feb NEWA

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

AB ALEMBIC 0.05% A213774 001 Jan 26, 2026 Jan NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

>A>	AB3	MACLEODS PHARMS LTD	120MG	A218744	001	Feb 27, 2026	Feb NEWA
>A>	AB3		180MG	A218744	002	Feb 27, 2026	Feb NEWA
>A>	AB3		240MG	A218744	003	Feb 27, 2026	Feb NEWA
>A>	AB3		300MG	A218744	004	Feb 27, 2026	Feb NEWA
>A>	AB3		360MG	A218744	005	Feb 27, 2026	Feb NEWA

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@ ZYDUS LIFESCIENCES 30MG
@ 60MG
@ 90MG
@ 120MG

A219253	001	Aug 08, 2025	Jan DISC
A219253	002	Aug 08, 2025	Jan DISC
A219253	003	Aug 08, 2025	Jan DISC
A219253	004	Aug 08, 2025	Jan DISC

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>A>	@	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Feb CAHN
>A>	AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb CAHN
>A>	@		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb DISC
>A>	AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb CAHN
>A>	@		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb DISC
>D>	@	NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Feb CAHN
>D>	AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Feb CAHN
>D>	AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Feb CAHN

DOFETILIDE

CAPSULE;ORAL
DOFETILIDE

>A>	@	INGENUS PHARMS LLC	0.125MG	A212410	001	Dec 27, 2019	Feb CAHN
>A>	@		0.25MG	A212410	002	Dec 27, 2019	Feb CAHN
>A>	@		0.5MG	A212410	003	Dec 27, 2019	Feb CAHN
>D>	@	NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019	Feb CAHN
>D>	@		0.25MG	A212410	002	Dec 27, 2019	Feb CAHN
>D>	@		0.5MG	A212410	003	Dec 27, 2019	Feb CAHN
	@	STRIDES PHARMA INTL	0.125MG	A208519	001	Oct 09, 2018	Jan DISC
	@		0.25MG	A208519	002	Oct 09, 2018	Jan DISC
	@		0.5MG	A208519	003	Oct 09, 2018	Jan DISC

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

>D>	AB	LUPIN LTD	23MG	A202782	001	Oct 30, 2015	Feb DISC
>A>	@		23MG	A202782	001	Oct 30, 2015	Feb DISC

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

AP	CAPLIN		4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan CAHN
----	--------	--	--------------------	---------	-----	--------------	----------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION
DOXORUBICIN HYDROCHLORIDE

AB	QILU PHARM HAINAN		20MG/10ML (2MG/ML)	A219881	001	Feb 03, 2026	Jan NEWA
AB			50MG/25ML (2MG/ML)	A219881	002	Feb 03, 2026	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

AB	AIPING PHARM INC		40MG	A219978	001	Oct 01, 2025	Jan CAHN
----	------------------	--	------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION
DOXYCYCLINE HYCLATE

>A>	AP	AVET LIFESCIENCES	EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb NEWA
>A>	@		EQ 100MG BASE/VIAL	A203276	001	Feb 19, 2026	Feb DISC

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ APOTEX EQ 75MG BASE
@ EQ 150MG BASE

A209243	001	Apr 15, 2019	Jan DISC
A209243	002	Apr 15, 2019	Jan DISC

DRONABINOL

SOLUTION;ORAL
SYNDROS

@ +	WELLHOUSE PHARMA	5MG/ML	N205525	001	Mar 23, 2017	Jan CAHN
-----	------------------	--------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

>A>	+	ALMATICA	EQ 80MG BASE	N219131	001	Feb 27, 2026	Feb NEWA
>A>	+		EQ 90MG BASE	N219131	002	Feb 27, 2026	Feb NEWA
>A>	+		EQ 120MG BASE	N219131	003	Feb 27, 2026	Feb NEWA

EFINACONAZOLE

SOLUTION;TOPICAL
EFINACONAZOLE

>A>	AB	ALEMBIC	10%	A212027	001	Feb 23, 2026	Feb NEWA
-----	----	---------	-----	---------	-----	--------------	----------

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL
ELETRIPTAN HYDROBROMIDE

>A>	@	CARLSBAD	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb CAHN
>A>	@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb CAHN
>D>	@	YUNG SHIN PHARM	EQ 20MG BASE	A209680	001	Jul 13, 2020	Feb CAHN
>D>	@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Feb CAHN

ELIGLUSTAT TARTRATE

CAPSULE;ORAL
ELIGLUSTAT TARTRATE

>D>	AB	CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Feb DISC
>A>	@		EQ 84MG BASE	A212369	001	Dec 10, 2024	Feb DISC

ELTROMBOPAG OLAMINE

TABLET;ORAL
ELTROMBOPAG OLAMINE

AB		AMNEAL	EQ 12.5MG ACID	A212884	001	Jan 14, 2026	Jan NEWA
AB			EQ 25MG ACID	A212884	003	Jan 14, 2026	Jan NEWA
AB			EQ 50MG ACID	A212884	002	Jan 14, 2026	Jan NEWA
AB			EQ 75MG ACID	A212884	004	Jan 14, 2026	Jan NEWA
AB		MSN	EQ 12.5MG ACID	A220250	001	Jan 14, 2026	Jan NEWA
AB			EQ 25MG ACID	A220250	002	Jan 14, 2026	Jan NEWA
AB			EQ 50MG ACID	A220250	003	Jan 14, 2026	Jan NEWA
AB			EQ 75MG ACID	A220250	004	Jan 14, 2026	Jan NEWA
AB		SOMERSET THERAPS LLC	EQ 12.5MG ACID	A219638	001	Jan 14, 2026	Jan NEWA
AB			EQ 25MG ACID	A219638	002	Jan 14, 2026	Jan NEWA
AB			EQ 50MG ACID	A219638	003	Jan 14, 2026	Jan NEWA
AB			EQ 75MG ACID	A219638	004	Jan 14, 2026	Jan NEWA
AB		ZYDUS PHARMS	EQ 12.5MG ACID	A216281	001	Jan 14, 2026	Jan NEWA
AB			EQ 25MG ACID	A216281	002	Jan 14, 2026	Jan NEWA
AB			EQ 50MG ACID	A216281	003	Jan 14, 2026	Jan NEWA
AB			EQ 75MG ACID	A216281	004	Jan 14, 2026	Jan NEWA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

AB		APOTEX	200MG;EQ 25MG BASE;EQ 25MG BASE	A214095	001	Jan 30, 2026	Jan NFTG
AB		ODEFSEY					
AB		+! GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Jan CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	LAURUS	200MG;EQ 25MG BASE;300MG	A220232	001	Mar 04, 2026	Feb NEWA
-----	----	--------	--------------------------	---------	-----	--------------	----------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL
ERYTHROMYCIN

>A>	AB	CARNEGIE	250MG	A062746	001	Dec 22, 1986	Feb CAHN
>D>	AB	PHARMOBEDIENT	250MG	A062746	001	Dec 22, 1986	Feb CAHN

TABLET;ORAL

ERYTHROMYCIN

>A>	AB	CARNEGIE	250MG	A 061621	001		Feb	CAHN
>A>	AB		500MG	A 061621	002		Feb	CAHN
>D>	AB	PHARMOBEDIENT	250MG	A 061621	001		Feb	CAHN
>D>	AB		500MG	A 061621	002		Feb	CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

>A>	AB	CARNEGIE	250MG	A 062298	001		Feb	CAHN
>A>	AB		333MG	A 062298	003	Mar 29, 1982	Feb	CAHN
>A>	AB	!	500MG	A 062298	002		Feb	CAHN
>D>	AB	PHARMOBEDIENT	250MG	A 062298	001		Feb	CAHN
>D>	AB		333MG	A 062298	003	Mar 29, 1982	Feb	CAHN
>D>	AB	!	500MG	A 062298	002		Feb	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

E.E.S. 400

>A>		@ CARNEGIE	EQ 400MG BASE	A 061905	001		Feb	CAHN
>A>	BX	!	EQ 400MG BASE	A 061905	002	Aug 12, 1982	Feb	CAHN
>D>		@ PHARMOBEDIENT	EQ 400MG BASE	A 061905	001		Feb	CAHN
>D>	BX	!	EQ 400MG BASE	A 061905	002	Aug 12, 1982	Feb	CAHN
<u>ERYTHROMYCIN ETHYLSUCCINATE</u>								
>A>	BX	! CARNEGIE	EQ 400MG BASE	A 061904	001		Feb	CAHN
>D>	BX	! PHARMOBEDIENT	EQ 400MG BASE	A 061904	001		Feb	CAHN

ESTRADIOL

GEL;TRANSDERMAL

ESTRADIOL

>D>	AB	QUAGEN	0.1% (0.25GM/PACKET)	A 217863	001	Jul 12, 2024	Feb	CAHN
>D>	AB		0.1% (0.5GM/PACKET)	A 217863	002	Jul 12, 2024	Feb	CAHN
>D>	AB		0.1% (0.75GM/PACKET)	A 217863	003	Jul 12, 2024	Feb	CAHN
>D>	AB		0.1% (1GM/PACKET)	A 217863	004	Jul 12, 2024	Feb	CAHN
>D>	AB		0.1% (1.25GM/PACKET)	A 217863	005	Jul 12, 2024	Feb	CAHN
>A>	AB	SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A 217863	001	Jul 12, 2024	Feb	CAHN
>A>	AB		0.1% (0.5GM/PACKET)	A 217863	002	Jul 12, 2024	Feb	CAHN
>A>	AB		0.1% (0.75GM/PACKET)	A 217863	003	Jul 12, 2024	Feb	CAHN
>A>	AB		0.1% (1GM/PACKET)	A 217863	004	Jul 12, 2024	Feb	CAHN
>A>	AB		0.1% (1.25GM/PACKET)	A 217863	005	Jul 12, 2024	Feb	CAHN
	AB	XIROMED	0.1% (0.25GM/PACKET)	A 211783	001	Aug 10, 2022	Jan	CAHN
	AB		0.1% (0.5GM/PACKET)	A 211783	002	Aug 10, 2022	Jan	CAHN
	AB		0.1% (1GM/PACKET)	A 211783	003	Aug 10, 2022	Jan	CAHN

GEL, METERED;TRANSDERMAL

ESTRADIOL

AB		LONG GROVE PHARMS	0.06% (1.25GM/ACTIVATION)	A 215096	001	Feb 02, 2026	Jan	NEWA
----	--	-------------------	---------------------------	----------	-----	--------------	-----	------

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

	+	MILLCENT MFG PR	EQ 0.05MG BASE/24HR	N 021367	001	Mar 20, 2003	Jan	CAHN
	+	!	EQ 0.1MG BASE/24HR	N 021367	002	Mar 20, 2003	Jan	CAHN

ETODOLAC

TABLET;ORAL

ETODOLAC

	@	SENORES PHARMS	400MG	A 074839	001	Jul 11, 1997	Jan	CAHN
--	---	----------------	-------	----------	-----	--------------	-----	------

ETOPOSIDE

CAPSULE;ORAL

ETOPOSIDE

AB		! MYLAN	50MG	A 075635	001	Sep 19, 2001	Jan	CTEC
----	--	---------	------	----------	-----	--------------	-----	------

VEPESID

AB		+ ONESOURCE SPECIALTY	50MG	N 019557	001	Dec 30, 1986	Jan	CMFD
----	--	-----------------------	------	----------	-----	--------------	-----	------

INJECTABLE;INTRAVENOUS

AVOPEF

>A>		+!	AVYXA HOLDINGS	100MG/5ML (20MG/ML)	N 220200	001	Feb 13, 2026	Feb	NEWA
-----	--	----	----------------	---------------------	----------	-----	--------------	-----	------

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

>A>	AB	EUGIA PHARMA	0.25MG	A219533	001	Feb 25, 2026	Feb NEWA
>A>	AB		0.5MG	A219533	002	Feb 25, 2026	Feb NEWA
>A>	AB		0.75MG	A219533	003	Feb 25, 2026	Feb NEWA
>A>	AB		1MG	A219533	004	Feb 25, 2026	Feb NEWA
		@ PH HEALTH	2.5MG	A207934	001	Dec 09, 2019	Jan DISC
		@	5MG	A207934	002	Dec 09, 2019	Jan DISC
		@	7.5MG	A207934	003	Dec 09, 2019	Jan DISC
		@	10MG	A207934	004	Dec 09, 2020	Jan DISC

TABLET, FOR SUSPENSION;ORAL

EVEROLIMUS

AB		BIOCON PHARMA	2MG	A217216	001	Jan 09, 2026	Jan NEWA
AB			3MG	A217216	002	Jan 09, 2026	Jan NEWA
AB			5MG	A217216	003	Jan 09, 2026	Jan NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

>D>	AB	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Feb DISC
>A>		@	10MG;10MG	A202968	001	Apr 26, 2017	Feb DISC
>D>	AB		10MG;20MG	A202968	002	Apr 26, 2017	Feb DISC
>A>		@	10MG;20MG	A202968	002	Apr 26, 2017	Feb DISC
>D>	AB		10MG;40MG	A202968	003	Apr 26, 2017	Feb DISC
>A>		@	10MG;40MG	A202968	003	Apr 26, 2017	Feb DISC
>D>	AB		10MG;80MG	A202968	004	Apr 26, 2017	Feb DISC
>A>		@	10MG;80MG	A202968	004	Apr 26, 2017	Feb DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

>A>	AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Feb CAHN
>A>	AB	CONTRACT PHARMACAL	40MG/5ML	A219603	001	Mar 09, 2026	Feb NEWA
>D>	AB	PHARMOBEDIENT	40MG/5ML	A217137	001	Jul 07, 2023	Feb CAHN

TABLET;ORAL

FAMOTIDINE

AB		VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan CAHN
AB			40MG	A215630	002	Jan 07, 2022	Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

>A>	AB	ZYDUS LIFESCIENCES	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb CAHN
>D>	AB	ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb CAHN

FENOFIBRATE

CAPSULE;ORAL

LIPOFEN

@ + CIPHER PHARMS INC 100MG

N021612	002	Jan 11, 2006	Jan CRLD
---------	-----	--------------	----------

TABLET;ORAL

FENOFIBRATE

AB		MACLEODS PHARMS LTD	54MG	A210379	001	Jan 21, 2026	Jan NEWA
AB			160MG	A210379	002	Jan 21, 2026	Jan NEWA

TRIGLIDE

@ JAGOTEC 50MG

N021350	001	May 07, 2005	Jan CAHN
---------	-----	--------------	----------

@ + 160MG

N021350	002	May 07, 2005	Jan CAHN
---------	-----	--------------	----------

FERRIC CITRATE

TABLET;ORAL

AURYXIA

>D>		+! KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb CFTG
>A>	AB	+!	EQ 210MG IRON	N205874	001	Sep 05, 2014	Feb CFTG
>A>		FERRIC CITRATE					
>A>	AB	TEVA PHARMS USA	EQ 210MG IRON	A212563	001	Mar 11, 2026	Feb NFTG

FIDAXOMICIN

TABLET; ORAL

FIDAXOMICIN

AB	APOTEX	200MG	A219559	001	Feb 02, 2026	Jan	NEWA
AB	TORRENT	200MG	A220374	001	Jan 27, 2026	Jan	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

@ +	CAPLIN ONE LABS	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan	CAHN
-----	-----------------	--------------------	---------	-----	--------------	-----	------

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB	HIBROW HLTHCARE	0.1MG	A220308	001	Feb 10, 2026	Jan	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

>A>	AT	+!	EUROFARMA	0.01%	N012787	004	Feb	CAHN
>A>	AT	+!		0.025%	N012787	002	Feb	CAHN
>A>	AT	+!		0.025%	N012787	005	Feb	CAHN
>D>	AT	+!	MEDIMETRIKS PHARMS	0.01%	N012787	004	Feb	CAHN
>D>	AT	+!		0.025%	N012787	002	Feb	CAHN
>D>	AT	+!		0.025%	N012787	005	Feb	CAHN

SYNALAR-HP

>A>	@		EUROFARMA	0.2%	N016161	002	Feb	CAHN
>D>	@		MEDIMETRIKS PHARMS	0.2%	N016161	002	Feb	CAHN

OINTMENT; TOPICAL

SYNALAR

>A>	AT	+!	EUROFARMA	0.025%	N013960	001	Feb	CAHN
>D>	AT	+!	MEDIMETRIKS PHARMS	0.025%	N013960	001	Feb	CAHN

SOLUTION; TOPICAL

SYNALAR

>A>	AT	+!	EUROFARMA	0.01%	N015296	001	Feb	CAHN
>D>	AT	+!	MEDIMETRIKS PHARMS	0.01%	N015296	001	Feb	CAHN

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

>A>	!		EUROFARMA	0.025%;EQ 3.5MG BASE/GM	A060700	001	Feb	CAHN
>D>	!		MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	Feb	CAHN

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC

FLUOROMETHOLONE

AB	DIFGEN PHARMS	0.1%	A218819	001	Feb 12, 2026	Jan	NEWA
----	---------------	------	---------	-----	--------------	-----	------

FLUOROURACIL

SOLUTION; INTRAVENOUS

FAVLYXA

>A>	+!		AVYXA HOLDINGS	250MG/10ML (25MG/ML)	N220201	001	Feb 20, 2026	Feb	NEWA
-----	----	--	----------------	----------------------	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1		APNAR PHARMA LP	EQ 10MG BASE	A075049	001	Aug 02, 2001	Feb	CAHN
>D>	AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002	Feb	CAHN
>D>	AB			EQ 40MG BASE	A075049	003	Jan 29, 2002	Feb	CAHN
>A>	AB1		SENORES PHARMS	EQ 10MG BASE	A075049	001	Aug 02, 2001	Feb	CAHN
>A>	AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002	Feb	CAHN
>A>	AB			EQ 40MG BASE	A075049	003	Jan 29, 2002	Feb	CAHN
		@	STRIDES PHARMA INTL	EQ 10MG BASE	A076922	001	Dec 16, 2004	Jan	DISC
		@		EQ 20MG BASE	A076922	002	Dec 16, 2004	Jan	DISC
		@		EQ 40MG BASE	A076922	003	Dec 16, 2004	Jan	DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>D>	AB	BRECKENRIDGE	1MG	A216891	001	Nov 15, 2022	Feb	DISC
>A>	@		1MG	A216891	001	Nov 15, 2022	Feb	DISC
>D>	AB		2.5MG	A216891	002	Nov 15, 2022	Feb	DISC
>A>	@		2.5MG	A216891	002	Nov 15, 2022	Feb	DISC
>D>	AB		5MG	A216891	003	Nov 15, 2022	Feb	DISC
>A>	@		5MG	A216891	003	Nov 15, 2022	Feb	DISC
>D>	AB		10MG	A216891	004	Nov 15, 2022	Feb	DISC
>A>	@		10MG	A216891	004	Nov 15, 2022	Feb	DISC
	AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Jan	CAHN
	AB		2.5MG	A215141	002	Oct 20, 2021	Jan	CAHN
	AB		5MG	A215141	003	Oct 20, 2021	Jan	CAHN
	AB		10MG	A215141	004	Oct 20, 2021	Jan	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

>A>	@	HIKMA INTL PHARMS	15MG	A071108	002	Dec 08, 1986	Feb	CMS1
-----	---	-------------------	------	---------	-----	--------------	-----	------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

+	!	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023	Jan	CHRS
---	---	---------------	--------------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

AEROSOL, METERED;INHALATION

FLOVENT HFA

>D>	+	!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004	Feb	CFTG
>A>	AB	+		0.044MG/INH	N021433	003	May 14, 2004	Feb	CFTG
>A>			FLUTICASONE PROPIONATE						
>A>	AB		GLENMARK SPECIT	0.044MG/INH	A219602	001	Mar 03, 2026	Feb	NFTG

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO RESPICLICK

+	!	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan	CHRS
+	!		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan	CHRS

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

AB		RESPIRENT PHARMS	0.1MG/INH;EQ 0.05MG BASE/INH	A214464	001	Jan 12, 2026	Jan	NEWA
AB			0.25MG/INH;EQ 0.05MG BASE/INH	A214464	002	Jan 12, 2026	Jan	NEWA

FOLIC ACID

SOLUTION;ORAL

QUIOFIC

+	!	CMP DEV LLC	0.2MG/ML	N216395	001	Jan 26, 2026	Jan	NEWA
---	---	-------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

FOLIC ACID

>D>	AA	+	!	WATSON LABS	1MG	A080680	001	Feb	CHRS
>A>	AA	+			1MG	A080680	001	Feb	CHRS

FONDAPARINUX SODIUM

SOLUTION;SUBCUTANEOUS

ARIIXTRA

AP	+	!	MYLAN IRELAND LTD	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jan	CDFR
AP	+	!		5MG/0.4ML	N021345	002	May 28, 2004	Jan	CDFR
AP	+	!		7.5MG/0.6ML	N021345	003	May 28, 2004	Jan	CDFR
AP	+	!		10MG/0.8ML	N021345	004	May 28, 2004	Jan	CDFR

FONDAPARINUX SODIUM

	@		BRIGHTGENE	2.5MG/0.5ML	A218312	001	Dec 18, 2024	Jan	CDFR
AP			DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jan	CDFR
AP				5MG/0.4ML	A091316	002	Jul 11, 2011	Jan	CDFR
AP				7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jan	CDFR
AP				10MG/0.8ML	A091316	004	Jul 11, 2011	Jan	CDFR
AP			EUGIA PHARMA	2.5MG/0.5ML	A206918	001	Dec 26, 2017	Jan	CDFR
AP				5MG/0.4ML	A206918	002	Dec 26, 2017	Jan	CDFR
AP				7.5MG/0.6ML	A206918	003	Dec 26, 2017	Jan	CDFR
AP				10MG/0.8ML	A206918	004	Dec 26, 2017	Jan	CDFR
	@		HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jan	CDFR

SOLUTION;SUBCUTANEOUS
FONDAPARINUX SODIUM

	@		5MG/0.4ML	A216493	002	Aug 19, 2024	Jan CDFR
	@		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jan CDFR
	@		10MG/0.8ML	A216493	004	Aug 19, 2024	Jan CDFR
AP		HENGRUI PHARMA	2.5MG/0.5ML	A206812	001	May 15, 2018	Jan CDFR
AP			5MG/0.4ML	A206812	002	May 15, 2018	Jan CDFR
AP			7.5MG/0.6ML	A206812	003	May 15, 2018	Jan CDFR
AP			10MG/0.8ML	A206812	004	May 15, 2018	Jan CDFR
AP		SCINOPHARM TAIWAN	2.5MG/0.5ML	A208615	001	Nov 14, 2018	Jan CDFR
AP			5MG/0.4ML	A208615	002	Nov 14, 2018	Jan CDFR
AP			7.5MG/0.6ML	A208615	003	Nov 14, 2018	Jan CDFR
AP			10MG/0.8ML	A208615	004	Nov 14, 2018	Jan CDFR

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE
@ CAPLIN

EQ	150MG	BASE/VIAL	A203939	001	Dec 08, 2020	Jan CAHN
----	-------	-----------	---------	-----	--------------	----------

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVA

>D>	AB	+!	ENDO OPERATIONS	EQ	2.5MG	BASE	N021006	001	Nov 08, 2001	Feb DISC
>A>		@	+	EQ	2.5MG	BASE	N021006	001	Nov 08, 2001	Feb DISC
			FROVATRIPTAN SUCCINATE							
>D>	AB		RENATA	EQ	2.5MG	BASE	A213891	001	Apr 06, 2022	Feb CHRS
>A>	AB		!	EQ	2.5MG	BASE	A213891	001	Apr 06, 2022	Feb CHRS

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP		MICRO LABS	10MG/ML	A218188	001	Jan 08, 2026	Jan NEWA
----	--	------------	---------	---------	-----	--------------	----------

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

>A>	AB		PRINSTON INC	100MG	A219814	001	Mar 06, 2026	Feb NEWA
>A>	AB			300MG	A219814	002	Mar 06, 2026	Feb NEWA
>A>	AB			400MG	A219814	003	Mar 06, 2026	Feb NEWA
>A>			SCIEGEN PHARMS	200MG	A204989	004	Mar 06, 2026	Feb NEWA

GALANTAMINE HYDROBROMIDE

TABLET; ORAL
GALANTAMINE HYDROBROMIDE

AB		SENORES PHARMS	EQ	4MG	BASE	A077593	001	Sep 11, 2008	Jan CAHN
AB			EQ	8MG	BASE	A077593	002	Sep 11, 2008	Jan CAHN
AB			EQ	12MG	BASE	A077593	003	Sep 11, 2008	Jan CAHN

GEFITINIB

TABLET; ORAL
GEFITINIB
@ APOTEX

250MG	A209532	001	Sep 23, 2022	Jan DISC
-------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

>D>	AP		NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb DISC
>A>		@		200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb DISC
>D>	AP			1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb DISC
>A>		@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb DISC
>D>	AP			2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb DISC
>A>		@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb DISC

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
GLATIRAMER ACETATE

AP		HYBIO	20MG/ML	A213382	001	Feb 11, 2026	Jan NEWA
AP			40MG/ML	A214022	001	Feb 11, 2026	Jan NEWA

GLIPIZIDE

TABLET;ORAL
GLIPIZIDE

>A>	AB	GRAVITI PHARMS	5MG	A219159	001	Mar 04, 2026	Feb	NEWA
>A>	AB		10MG	A219159	002	Mar 04, 2026	Feb	NEWA
		! RUBICON RESEARCH	15MG	A214874	004	Feb 04, 2026	Jan	NFTG

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC
NEOSPORIN

@	MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060582	001			Jan	DISC
---	----------------	---	---------	-----	--	--	-----	------

HALOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL
HALOBETASOL PROPIONATE

>D>	AB	PADAGIS ISRAEL	0.05%	A215266	001	Aug 11, 2023	Feb	CHRS
>A>	AB	!	0.05%	A215266	001	Aug 11, 2023	Feb	CHRS
>A>		!	0.05%	A215266	001	Aug 11, 2023	Feb	CTEC
>D>		LEXETTE						
>D>	AB	+! MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	Feb	DISC
>A>		@ +	0.05%	N210566	001	May 24, 2018	Feb	DISC

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM PRESERVATIVE FREE

>D>		@ + PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Feb	CMFD
>A>		+!	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Feb	CMFD

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL
HYDRALAZINE HYDROCHLORIDE

@	STRIDES PHARMA INTL	10MG	A087836	001	Oct 05, 1982	Jan	DISC
@		25MG	A086961	002		Jan	DISC
@		50MG	A086962	001		Jan	DISC
@		100MG	A088391	001	Sep 27, 1983	Jan	DISC

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL
HYDRA-ZIDE

@	STRIDES PHARMA INTL	25MG;25MG	A088957	001	Oct 21, 1985	Jan	DISC
@		50MG;50MG	A088946	001	Oct 21, 1985	Jan	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

>A>	AB	INGENUS PHARMS LLC	37.5MG;20MG	A215586	001	Apr 06, 2022	Feb	CAHN
>D>	AB	NOVAST LABS	37.5MG;20MG	A215586	001	Apr 06, 2022	Feb	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

@	STRIDES PHARMA INTL	15MG;250MG	A070614	002	Feb 02, 1987	Jan	CMS1
@		25MG;250MG	A070614	003	Feb 02, 1987	Jan	CMS1
@		30MG;500MG	A070614	004	Feb 02, 1987	Jan	CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

>D>	AB	! ALEMBIC	25MG;100MG	A202870	002	Nov 06, 2013	Feb	CHRS
>A>	AB		25MG;100MG	A202870	002	Nov 06, 2013	Feb	CHRS
>D>	AB	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Feb	CHRS
>A>	AB	!	50MG;100MG	A076792	003	Aug 20, 2004	Feb	CHRS

HYDROCORTISONE

TABLET;ORAL
HYDROCORTISONE

>A>	AB	APPCO	5MG	A220329	001	Feb 25, 2026	Feb	NEWA
>A>	AB		10MG	A220329	002	Feb 25, 2026	Feb	NEWA
>A>	AB		20MG	A220329	003	Feb 25, 2026	Feb	NEWA

HYDROCORTISONE BUTYRATE

OINTMENT;TOPICAL
HYDROCORTISONE BUTYRATE

>D>	AB	TARO	0.1%	A076842	001	Dec 27, 2004	Feb	CHRS
>A>	AB	!	0.1%	A076842	001	Dec 27, 2004	Feb	CHRS
>A>		!	0.1%	A076842	001	Dec 27, 2004	Feb	CTEC
>D>		LOCOID						
>D>	AB	+! PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	Feb	DISC
>A>		@ +	0.1%	N018652	001	Oct 29, 1982	Feb	DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION
HYDROCORTISONE SODIUM SUCCINATE

AP		APOTEX	EQ 100MG BASE/VIAL	A219856	001	Feb 05, 2026	Jan	NEWA
----	--	--------	--------------------	---------	-----	--------------	-----	------

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL
HYDROXYCHLOROQUINE SULFATE

AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

IDELALISIB

TABLET;ORAL

>A>		IDELALISIB						
>A>	AB	NATCO	100MG	A216921	001	Feb 17, 2026	Feb	NFTG
>A>	AB		150MG	A216921	002	Feb 17, 2026	Feb	NFTG
		ZYDELIG						
>D>		+ GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014	Feb	CFTG
>A>	AB	+	100MG	N205858	001	Jul 23, 2014	Feb	CFTG
>D>		+!	150MG	N205858	002	Jul 23, 2014	Feb	CFTG
>A>	AB	+!	150MG	N205858	002	Jul 23, 2014	Feb	CFTG

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

>D>	AB	SUN PHARM	EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb	DISC
>A>		@	EQ 100MG BASE	A078340	001	Dec 03, 2015	Feb	DISC
>D>	AB		EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb	DISC
>A>		@	EQ 400MG BASE	A078340	002	Dec 03, 2015	Feb	DISC

IOMEPROL

SOLUTION;INTRA-ARTERIAL
IOMERUV

>D>		@ + BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb	CMFD
>A>		+!	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Feb	CMFD
>D>		@ +	40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb	CMFD
>A>		+!	40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Feb	CMFD
>D>		@ +	70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb	CMFD
>A>		+!	70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Feb	CMFD
>D>		@ +	80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb	CMFD
>A>		+!	80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Feb	CMFD

SOLUTION;INTRAVENOUS
IOMERUV

>D>		@ + BRACCO	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb	CMFD
>A>		+!	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Feb	CMFD
>D>		@ +	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb	CMFD
>A>		+!	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Feb	CMFD
>D>		@ +	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb	CMFD
>A>		+!	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Feb	CMFD
>D>		@ +	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb	CMFD

SOLUTION; INTRAVENOUS								
IOMERVU								
>A>	+	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Feb	CMFD	
<u>IPRATROPIUM BROMIDE</u>								
AEROSOL, METERED; INHALATION								
ATROVENT HFA								
>D>	+	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	Feb CFTG	
>A>	AB	+	0.021MG/INH	N021527	001	Nov 27, 2004	Feb CFTG	
>A>	IPRATROPIUM BROMIDE							
>A>	AB	ARMSTRONG PHARMS	0.021MG/INH	A217953	001	Feb 23, 2026	Feb NFTG	
<u>ISOSULFAN BLUE</u>								
SOLUTION; SUBCUTANEOUS								
ISOSULFAN BLUE								
	!	MYLAN INSTITUTIONAL	10MG/ML (10MG/ML)	A090874	002	Jan 28, 2026	Jan NFTG	
	!		30MG/3ML (10MG/ML)	A090874	003	Jan 28, 2026	Jan NFTG	
<u>IVABRADINE HYDROCHLORIDE</u>								
TABLET; ORAL								
CORLANOR								
	@	+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan DISC
	@	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan DISC
IVABRADINE HYDROCHLORIDE								
AB	!	INGENUS PHARMS LLC	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan CHRS	
<u>IVERMECTIN</u>								
TABLET; ORAL								
IVERMECTIN								
>A>	AB	E5 PHARMA	3MG	A216808	001	Mar 09, 2026	Feb NEWA	
>A>	AB	ZYDUS LIFESCIENCES	3MG	A216863	001	Feb 26, 2026	Feb NEWA	
<u>KETOCONAZOLE</u>								
CREAM; TOPICAL								
KETOCONAZOLE								
	@	PADAGIS US	2%	A215185	001	Nov 17, 2021	Jan DISC	
<u>LACOSAMIDE</u>								
SOLUTION; INTRAVENOUS								
LACOSAMIDE								
AP		ANTHEA PHARMA	200MG/20ML (10MG/ML)	A220268	001	Jan 21, 2026	Jan NEWA	
SOLUTION; ORAL								
LACOSAMIDE								
>D>	AA	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Feb DISC	
>A>		@	10MG/ML	A206355	001	Sep 26, 2022	Feb DISC	
	AA	INDOCO	10MG/ML	A220386	001	Jan 29, 2026	Jan NEWA	
	AA	REGCON HOLDINGS	10MG/ML	A220386	001	Jan 29, 2026	Jan CAHN	
<u>LAMIVUDINE</u>								
TABLET; ORAL								
LAMIVUDINE								
	@	LUPIN LTD	150MG	A205217	001	Dec 18, 2014	Jan DISC	
	@		300MG	A205217	002	Dec 18, 2014	Jan DISC	
<u>LAMOTRIGINE</u>								
TABLET, ORALLY DISINTEGRATING; ORAL								
LAMOTRIGINE								
>A>	AB	ALEMBIC	25MG	A217278	001	Feb 25, 2026	Feb NEWA	
>A>	AB		50MG	A217278	002	Feb 25, 2026	Feb NEWA	
>A>	AB		100MG	A217278	003	Feb 25, 2026	Feb NEWA	
>A>	AB		200MG	A217278	004	Feb 25, 2026	Feb NEWA	
	AB	TORRENT	25MG	A217100	001	Jan 08, 2026	Jan NEWA	
	AB		50MG	A217100	002	Jan 08, 2026	Jan NEWA	
	AB		100MG	A217100	003	Jan 08, 2026	Jan NEWA	
	AB		200MG	A217100	004	Jan 08, 2026	Jan NEWA	

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

>A>	@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Feb CAHN
>D>	@	PHARMOBEDIENT	0.005%	A202077	001	Feb 11, 2013	Feb CAHN

LENALIDOMIDE

CAPSULE;ORAL
LENALIDOMIDE

AB		ALVOGEN	2.5MG	A210480	005	Mar 06, 2023	Jan CAHN
AB			5MG	A210480	001	Aug 31, 2022	Jan CAHN
AB			10MG	A210480	002	Aug 31, 2022	Jan CAHN
AB			15MG	A210480	003	Aug 31, 2022	Jan CAHN
AB			20MG	A210480	006	Mar 06, 2023	Jan CAHN
AB			25MG	A210480	004	Aug 31, 2022	Jan CAHN
AB		CIPLA	5MG	A213165	001	Feb 02, 2026	Jan NEWA
AB			10MG	A213165	002	Feb 02, 2026	Jan NEWA
AB			15MG	A213165	003	Feb 02, 2026	Jan NEWA
AB			20MG	A213165	004	Feb 02, 2026	Jan NEWA
AB			25MG	A213165	005	Feb 02, 2026	Jan NEWA
AB		TORRENT	2.5MG	A213405	005	Feb 10, 2026	Jan NEWA
AB			5MG	A213405	006	Feb 10, 2026	Jan NEWA

LEUCOVORIN CALCIUM

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
LEUCOVORIN CALCIUM

>A>	@	INGENUS PHARMS LLC	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Feb CAHN
>D>	@	NOVAST LABS	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Feb CAHN
>A>		VYKOURA					
>A>	+!	AVYXA HOLDINGS	EQ 50MG BASE/5ML (EQ 10MG BASE/ML)	N220406	001	Feb 03, 2026	Feb NEWA
>A>	+!		EQ 350MG BASE/35ML (EQ 10MG BASE/ML)	N220406	002	Feb 03, 2026	Feb NEWA
>A>	+!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	N220406	003	Feb 03, 2026	Feb NEWA

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

>D>	AP	RK PHARMA	14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Feb CAHN
>A>	AP	SOMERSET THERAPS LLC	14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Feb CAHN

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS
CAMCEVI ETM

+!	ACCORD	EQ 21MG BASE	N219745	001	Aug 25, 2025	Jan CAHN
----	--------	--------------	---------	-----	--------------	----------

LEVETIRACETAM

TABLET;ORAL
LEVETIRACETAM

AB		SENORES PHARMS	250MG	A076920	001	Jan 15, 2009	Jan CAHN
AB			500MG	A076920	002	Jan 15, 2009	Jan CAHN
AB			750MG	A076920	003	Jan 15, 2009	Jan CAHN
AB			1GM	A078904	001	Jan 15, 2009	Jan CAHN

LIDOCAINE

PATCH;TOPICAL
LIDOCAINE

>D>	AB	USPHARMA	5%	A207059	001	Feb 09, 2026	Feb DISC
>A>	@		5%	A207059	001	Feb 09, 2026	Feb DISC
	AB		5%	A207059	001	Feb 09, 2026	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP		ANTHEA PHARMA	2%	A219535	002	Feb 06, 2026	Jan NEWA
----	--	---------------	----	---------	-----	--------------	----------

LIRAGLUTIDESOLUTION;SUBCUTANEOUS
LIRAGLUTIDE

>A>	AP1	BIOCON PHARMA	18MG/3ML (6MG/ML)	A215245	001	Mar 11, 2026	Feb NEWA
>A>	AP2		18MG/3ML (6MG/ML)	A217063	001	Feb 24, 2026	Feb NEWA
>A>	AP2	ORBICULAR	18MG/3ML (6MG/ML)	A217234	001	Feb 24, 2026	Feb NEWA
	AP1		18MG/3ML (6MG/ML)	A217590	001	Jan 14, 2026	Jan NEWA

LOMITAPIDE MESYLATECAPSULE;ORAL
JUXTAPID

>A>		+ CHIESI	EQ 2MG BASE	N203858	007	Feb 25, 2026	Feb NEWA
-----	--	----------	-------------	---------	-----	--------------	----------

LUBIPROSTONECAPSULE;ORAL
LUBIPROSTONE

AB		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan CMFD
AB			24MCG	A209450	002	Nov 30, 2021	Jan CMFD

MACIMORELIN ACETATEFOR SOLUTION;ORAL
MACRILEN

@	+	AETERNA ZENTARIS	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	Jan CAHN
---	---	------------------	--------------------	---------	-----	--------------	----------

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

>A>	@	INGENUS PHARMS LLC	5%	A206716	001	Jul 31, 2017	Feb CAHN
>D>	@	NOVAST LABS	5%	A206716	001	Jul 31, 2017	Feb CAHN

MAGNESIUM SULFATEINJECTABLE;INJECTION
MAGNESIUM SULFATE

!		BAXTER HLTHCARE CORP	3GM/100ML (30MG/ML)	A211966	004	Jan 08, 2026	Jan NFTG
---	--	----------------------	---------------------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>D>	AA	APNAR PHARMA LP	12.5MG	A087128	002		Feb CAHN
>D>	AA		25MG	A087128	001		Feb CAHN
>A>	AA	SENORES PHARMS	12.5MG	A087128	002		Feb CAHN
>A>	AA		25MG	A087128	001		Feb CAHN

MEMANTINE HYDROCHLORIDE

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>A>	AB	RENATA	5MG	A209527	001	May 07, 2018	Feb CAHN
>A>	AB		10MG	A209527	002	May 07, 2018	Feb CAHN
>D>	AB	SOMERSET THERAPS LLC	5MG	A209527	001	May 07, 2018	Feb CAHN
>D>	AB		10MG	A209527	002	May 07, 2018	Feb CAHN

MEPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
POLOCAINE

!		FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jan CHRS
!			2%	A089410	001	Dec 01, 1986	Jan CHRS

POLOCAINE-MPF

!		FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jan CHRS
!			1.5%	A089408	001	Dec 01, 1986	Jan CHRS
!			2%	A089409	001	Dec 01, 1986	Jan CHRS

MESALAMINECAPSULE, EXTENDED RELEASE;ORAL
MESALAMINE

>A>	AB	DIFGEN PHARMS	250MG	A219997	001	Mar 10, 2026	Feb NFTG
>A>	AB		500MG	A219997	002	Mar 10, 2026	Feb NEWA
>D>		+ TAKEDA PHARMS USA	250MG	N020049	001	May 10, 1993	Feb CFTG
>A>	AB		250MG	N020049	001	May 10, 1993	Feb CFTG

MESNA

INJECTABLE; INTRAVENOUS
MESNA

AP EUGIA PHARMA 100MG/ML A220518 001 Jan 27, 2026 Jan NEWA

TABLET; ORAL
MESNA

>A> AB INGENUS PHARMS LLC 400MG A218871 001 Jan 13, 2025 Feb CAHN
>D> AB NOVAST LABS 400MG A218871 001 Jan 13, 2025 Feb CAHN

METAXALONE

TABLET; ORAL
METAXALONE

>A> @ INGENUS PHARMS LLC 800MG A213836 001 Oct 21, 2020 Feb CAHN
>D> @ NOVAST LABS 800MG A213836 001 Oct 21, 2020 Feb CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB CHARTWELL 625MG A075972 005 Jan 24, 2002 Jan CTEC
AB 750MG A075972 004 Jan 24, 2002 Jan CTEC
AB SCIEGEN PHARMS 625MG A203769 004 Feb 09, 2026 Jan NEWA
AB 750MG A203769 005 Feb 09, 2026 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

>D> AB3 APOTEX 500MG A213356 001 Dec 13, 2021 Feb DISC
>A> @ 500MG A213356 001 Dec 13, 2021 Feb DISC
>D> AB3 1GM A213356 002 Dec 13, 2021 Feb DISC
>A> @ 1GM A213356 002 Dec 13, 2021 Feb DISC
@ RK PHARMA 500MG A215629 001 Jun 20, 2023 Jan DISC
@ 1GM A215629 002 Jun 20, 2023 Jan DISC

METHADONE HYDROCHLORIDE

SOLUTION; ORAL
METHADONE HYDROCHLORIDE

>D> @ VISTAPHARM LLC 5MG/5ML A090707 001 Jun 30, 2010 Feb CMFD
>A> AA 5MG/5ML A090707 001 Jun 30, 2010 Feb CMFD

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB AJANTA PHARMA LTD 25MG A217408 001 Feb 09, 2026 Jan NEWA
AB 50MG A217408 002 Feb 09, 2026 Jan NEWA

METHENAMINE HIPPURATE

TABLET; ORAL
METHENAMINE HIPPURATE

>A> AB INGENUS PHARMS LLC 1GM A210068 001 Nov 27, 2020 Feb CAHN
>D> AB NOVAST LABS 1GM A210068 001 Nov 27, 2020 Feb CAHN

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

>A> AA HLTHCARE 500MG A203550 001 Feb 08, 2017 Feb CAHN
>A> AA 750MG A203550 002 Feb 08, 2017 Feb CAHN
>D> AA PHARMOBEDIENT 500MG A203550 001 Feb 08, 2017 Feb CAHN
>D> AA 750MG A203550 002 Feb 08, 2017 Feb CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

AP CAPLIN ONE LABS EQ 50MG BASE/2ML (EQ 25MG A090039 001 Mar 31, 2009 Jan CAHN
BASE/ML)
AP EQ 250MG BASE/10ML (EQ 25MG A090039 002 Mar 31, 2009 Jan CAHN
BASE/ML)
AP EQ 1GM BASE/40ML (EQ 25MG A090029 001 Mar 31, 2009 Jan CAHN
BASE/ML)

METHYLENE BLUE

SOLUTION;INTRAVENOUS
METHYLENE BLUE

!	ZYDUS LIFESCIENCES	5MG/ML (5MG/ML)	A215636	003	Feb 02, 2026	Jan	NFTG
---	--------------------	-----------------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB1	!	DR REDDYS LABS SA	60MG	A078458	004	Jun 23, 2016	Feb	CHRS
>A>	AB1			60MG	A078458	004	Jun 23, 2016	Feb	CHRS
>D>	AB1		GRANULES	60MG	A211796	005	May 23, 2019	Feb	CHRS
>A>	AB1	!		60MG	A211796	005	May 23, 2019	Feb	CHRS

METHYLPREDNISOLONE

TABLET;ORAL
METHYLPREDNISOLONE

>A>	@		INGENUS PHARMS LLC	4MG	A210985	001	Jan 09, 2019	Feb	CAHN
>D>	@		NOVAST LABS	4MG	A210985	001	Jan 09, 2019	Feb	CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

AB			CAPLIN	40MG/ML	A220556	001	Jan 26, 2026	Jan	NEWA
AB				80MG/ML	A220556	002	Jan 26, 2026	Jan	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SPRAY, METERED;NASAL
GIMOTI

>D>		+	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Feb	CAHN
>A>		+	QOL MEDCL	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Feb	CAHN

TABLET;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

@			STRIDES PHARMA INTL	EQ 10MG BASE	A070581	001	Oct 17, 1985	Jan	DISC
---	--	--	---------------------	--------------	---------	-----	--------------	-----	------

METRONIDAZOLE

GEL;TOPICAL
METRONIDAZOLE

>A>	AB		ZYDUS LIFESCIENCES	0.75%	A220095	001	Feb 13, 2026	Feb	NEWA
-----	----	--	--------------------	-------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION
METRO I.V. IN PLASTIC CONTAINER

@	+		B BRAUN	500MG/100ML	N018900	001	Sep 29, 1983	Jan	DISC
---	---	--	---------	-------------	---------	-----	--------------	-----	------

METRONIDAZOLE IN PLASTIC CONTAINER

AP		!	INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Jan	CHRS
----	--	---	-----------	-------------	---------	-----	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

>A>	AB		INGENUS PHARMS LLC	150MG	A214352	001	Jan 25, 2021	Feb	CAHN
>A>	AB			200MG	A214352	002	Jan 25, 2021	Feb	CAHN
>A>	AB			250MG	A214352	003	Jan 25, 2021	Feb	CAHN
>D>	AB		NOVAST LABS	150MG	A214352	001	Jan 25, 2021	Feb	CAHN
>D>	AB			200MG	A214352	002	Jan 25, 2021	Feb	CAHN
>D>	AB			250MG	A214352	003	Jan 25, 2021	Feb	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP			HISUN PHARM HANGZHOU	EQ 50MG BASE/VIAL	A219712	001	Jan 21, 2026	Jan	NEWA
AP				EQ 100MG BASE/VIAL	A219712	002	Jan 21, 2026	Jan	NEWA
>A>	AP		YICHANG HUMANWELL	EQ 50MG BASE/VIAL	A219518	001	Feb 24, 2026	Feb	NEWA
>A>	AP			EQ 100MG BASE/VIAL	A219518	002	Feb 24, 2026	Feb	NEWA

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

AB			AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Jan	CMFD
AB				25MG	A205081	002	Apr 22, 2016	Jan	CMFD
AB				50MG	A205081	003	Apr 22, 2016	Jan	CMFD
AB				100MG	A205081	004	Apr 22, 2016	Jan	CMFD
AB			BRECKENRIDGE	12.5MG	A205071	001	Jan 27, 2016	Jan	CMFD
AB				25MG	A205071	002	Jan 27, 2016	Jan	CMFD

<u>TABLET;ORAL</u>									
MILNACIPRAN HYDROCHLORIDE									
AB			50MG		A205071	003	Jan 27, 2016	Jan	CMFD
AB			100MG		A205071	004	Jan 27, 2016	Jan	CMFD
>D>	@	HETERO LABS LTD V	12.5MG		A205147	001	Oct 03, 2024	Feb	CMFD
>A>	AB		12.5MG		A205147	001	Oct 03, 2024	Feb	CMFD
>D>	@		25MG		A205147	002	Oct 03, 2024	Feb	CMFD
>A>	AB		25MG		A205147	002	Oct 03, 2024	Feb	CMFD
>D>	@		50MG		A205147	003	Oct 03, 2024	Feb	CMFD
>A>	AB		50MG		A205147	003	Oct 03, 2024	Feb	CMFD
>D>	@		100MG		A205147	004	Oct 03, 2024	Feb	CMFD
>A>	AB		100MG		A205147	004	Oct 03, 2024	Feb	CMFD
SAVELLA									
AB	+	ABBVIE	12.5MG		N022256	001	Jan 14, 2009	Jan	CTEC
AB	+		25MG		N022256	002	Jan 14, 2009	Jan	CTEC
AB	+	!	50MG		N022256	003	Jan 14, 2009	Jan	CTEC
AB	+		100MG		N022256	004	Jan 14, 2009	Jan	CTEC
>A>	<u>MILSAPERIDONE</u>								
>A>	TABLET;ORAL								
>A>	BYSANTI								
>A>	+	!	VANDA PHARMS INC	1MG	N220358	001	Feb 20, 2026	Feb	NEWA
>A>	+			2MG	N220358	002	Feb 20, 2026	Feb	NEWA
>A>	+			4MG	N220358	003	Feb 20, 2026	Feb	NEWA
>A>	+			6MG	N220358	004	Feb 20, 2026	Feb	NEWA
>A>	+			8MG	N220358	005	Feb 20, 2026	Feb	NEWA
>A>	+			10MG	N220358	006	Feb 20, 2026	Feb	NEWA
>A>	+			12MG	N220358	007	Feb 20, 2026	Feb	NEWA
<u>MIRABEGRON</u>									
FOR SUSPENSION, EXTENDED RELEASE;ORAL									
MIRABEGRON									
AB		ALKEM LABS LTD	8MG/ML		A219323	001	Jan 20, 2026	Jan	NFTG
AB		MYRBETRIQ GRANULES							
AB	+	!	APGDI	8MG/ML	N213801	001	Mar 25, 2021	Jan	CFTG
<u>MIRTAZAPINE</u>									
TABLET;ORAL									
MIRTAZAPINE									
AB		NOVITIUM PHARMA	7.5MG		A219919	001	Feb 02, 2026	Jan	NEWA
AB			15MG		A219919	002	Feb 02, 2026	Jan	NEWA
AB			30MG		A219919	003	Feb 02, 2026	Jan	NEWA
AB			45MG		A219919	004	Feb 02, 2026	Jan	NEWA
<u>MITAPIVAT SULFATE</u>									
TABLET;ORAL									
AQVESME									
	+	!	AGIOS PHARMS INC	EQ 100MG BASE	N216196	004	Dec 23, 2025	Jan	NEWA
<u>MONTELUKAST SODIUM</u>									
TABLET, CHEWABLE;ORAL									
MONTELUKAST SODIUM									
AB		SENORES PHARMS	EQ 4MG BASE		A201581	001	Aug 06, 2012	Jan	CAHN
AB			EQ 5MG BASE		A201581	002	Aug 06, 2012	Jan	CAHN
<u>MORPHINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
MORPHINE SULFATE									
	@		STRIDES PHARMA INTL	15MG	A075295	001	Oct 28, 1998	Jan	DISC
	@			30MG	A075295	002	Oct 28, 1998	Jan	DISC
	@			60MG	A075295	003	Oct 28, 1998	Jan	DISC
	@			100MG	A075295	004	Sep 15, 2000	Jan	DISC
	@			200MG	A075295	005	Sep 15, 2000	Jan	DISC
<u>MOXIFLOXACIN HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
MOXIFLOXACIN HYDROCHLORIDE									
>D>	AT1		FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Feb	DISC
>A>	@			EQ 0.5% BASE	A219475	001	Aug 04, 2025	Feb	DISC
TABLET;ORAL									
MOXIFLOXACIN HYDROCHLORIDE									
>A>	AB		MACLEODS PHARMS LTD	EQ 400MG BASE	A209143	001	Mar 02, 2026	Feb	NEWA

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLATE SODIUM

@	RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Jan DISC
@		EQ 360MG BASE	A091248	001	Jan 08, 2014	Jan DISC

NABUMETONE

TABLET;ORAL
NABUMETONE

!	LGM PHARMA	1GM	A203166	003	Aug 30, 2019	Jan CHRS
---	------------	-----	---------	-----	--------------	----------

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL
NAFTIFINE HYDROCHLORIDE

>D>	AB	AMNEAL	2%	A206960	001	Apr 10, 2017	Feb DISC
>A>	@		2%	A206960	001	Apr 10, 2017	Feb DISC

NALOXONE HYDROCHLORIDE

SPRAY;NASAL
REZENOPY

+	!	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Jan CMFD
---	---	-----------	------------	---------	-----	--------------	----------

>A> NAVEPEGITIDE

>A> POWDER;SUBCUTANEOUS
>A> YUWIWEL

>A>	+	!	ASCENDIS	1.3MG/VIAL	N219164	001	Feb 27, 2026	Feb NEWA
>A>	+	!		2.8MG/VIAL	N219164	002	Feb 27, 2026	Feb NEWA
>A>	+	!		5.5MG/VIAL	N219164	003	Feb 27, 2026	Feb NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATE

@	WATSON LABS	EQ 40MG BASE/ML;200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jan DISC
!	XGEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Jan CTEC
AT	!	EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Jan CHRS
!		EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Jan CTEC
AT	!	EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Jan CHRS
	NEOSPORIN G.U. IRRIGANT					
@	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001		Jan DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL
NICARDIPINE HYDROCHLORIDE

AB	SENORES PHARMS	20MG	A215377	001	Jul 17, 2023	Jan CAHN
AB		30MG	A215377	002	Jul 17, 2023	Jan CAHN

INJECTABLE;INJECTION
CARDENE

AP	+	CHIESI	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Jan CMFD
AP		SOMERSET THERAPS LLC	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Jan CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

>D>	AB	MYLAN	34MG	A091001	004	Jan 26, 2011	Feb DISC	
>A>	@		34MG	A091001	004	Jan 26, 2011	Feb DISC	
	SULAR							
>A>	AB	+	AZURITY	8.5MG	N020356	008	Jan 02, 2008	Feb CAHN
>A>	@	+		10MG	N020356	001	Feb 02, 1995	Feb CAHN
>A>	AB	+		17MG	N020356	007	Jan 02, 2008	Feb CAHN
>A>	@	+		20MG	N020356	002	Feb 02, 1995	Feb CAHN
>A>	@	+		25.5MG	N020356	006	Jan 02, 2008	Feb CAHN
>A>	@	+		30MG	N020356	003	Feb 02, 1995	Feb CAHN
>A>	+	!		34MG	N020356	005	Jan 02, 2008	Feb CAHN
>A>	@	+		40MG	N020356	004	Feb 02, 1995	Feb CAHN
>D>	AB	+	COVIS	8.5MG	N020356	008	Jan 02, 2008	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
SULAR

>D>	@ +	10MG	N020356	001	Feb 02, 1995	Feb	CAHN
>D>	AB +!	17MG	N020356	007	Jan 02, 2008	Feb	CAHN
>D>	@ +	20MG	N020356	002	Feb 02, 1995	Feb	CAHN
>D>	@ +	25.5MG	N020356	006	Jan 02, 2008	Feb	CAHN
>D>	@ +	30MG	N020356	003	Feb 02, 1995	Feb	CAHN
>D>	AB +!	34MG	N020356	005	Jan 02, 2008	Feb	CTEC
>A>	+!	34MG	N020356	005	Jan 02, 2008	Feb	CTEC
>D>	@ +	40MG	N020356	004	Feb 02, 1995	Feb	CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jan	CHRS
	+		0.2MG/HR	N020145	002	Apr 04, 1995	Jan	CHRS
	+		0.3MG/HR	N020145	003	Apr 04, 1995	Jan	CHRS
	+		0.6MG/HR	N020145	005	Apr 04, 1995	Jan	CHRS
	+		0.8MG/HR	N020145	006	Apr 04, 1995	Jan	CHRS
	NITROGLYCERIN							
AB2		MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Jan	CHRS
AB2			0.2MG/HR	A074559	003	Aug 30, 1996	Jan	CHRS
AB2			0.6MG/HR	A074559	001	Aug 30, 1996	Jan	CHRS

NOREPINEPHRINE BITARTRATE

SOLUTION;INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>A>	+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	004	Feb 06, 2026	Feb	NEWA
>A>	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	005	Feb 06, 2026	Feb	NEWA
>A>	+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	006	Feb 06, 2026	Feb	NEWA

NORETHINDRONE ACETATE

TABLET;ORAL
NORETHINDRONE ACETATE

>A>	AB	INGENUS PHARMS LLC	5MG	A206490	001	Nov 05, 2018	Feb	CAHN
>D>	AB	NOVAST LABS	5MG	A206490	001	Nov 05, 2018	Feb	CAHN

NYSTATIN

SUSPENSION;ORAL
NYSTATIN

AA		SCIEGEN PHARMS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jan	CAHN
AA		STERANCO HLTHCARE	100,000 UNITS/ML	A220367	001	Feb 05, 2026	Jan	NEWA

OLANZAPINE

POWDER;INTRAMUSCULAR
OLANZAPINE

AP		AM REGENT	10MG/VIAL	A201741	001	Mar 20, 2012	Jan	CDFR
>A>	AP	ANTHEA PHARMA	10MG/VIAL	A220323	001	Mar 05, 2026	Feb	NEWA
AP		ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Jan	CDFR
AP		EUGIA PHARMA	10MG/VIAL	A210968	001	Oct 22, 2020	Jan	CDFR
AP		OMNIVIUM PHARMS	10MG/VIAL	A219048	001	Jan 23, 2026	Jan	NEWA
AP		QILU	10MG/VIAL	A218116	001	May 16, 2025	Jan	CDFR
AP		SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Jan	CDFR
AP		UBI	10MG/VIAL	A211072	001	Jun 11, 2025	Jan	CDFR
	ZYPREXA							
AP	+!	CHEPLAPHARM	10MG/VIAL	N021253	001	Mar 29, 2004	Jan	CDFR

TABLET;ORAL
OLANZAPINE

>D>	@	SUNSHINE	2.5MG	A206238	001	Nov 19, 2018	Feb	CMFD
>A>	AB		2.5MG	A206238	001	Nov 19, 2018	Feb	CMFD
>D>	@		5MG	A206238	002	Nov 19, 2018	Feb	CMFD
>A>	AB		5MG	A206238	002	Nov 19, 2018	Feb	CMFD
>D>	@		7.5MG	A206238	003	Nov 19, 2018	Feb	CMFD
>A>	AB		7.5MG	A206238	003	Nov 19, 2018	Feb	CMFD
>D>	@		10MG	A206238	004	Nov 19, 2018	Feb	CMFD
>A>	AB		10MG	A206238	004	Nov 19, 2018	Feb	CMFD
>D>	@		15MG	A206238	005	Nov 19, 2018	Feb	CMFD
>A>	AB		15MG	A206238	005	Nov 19, 2018	Feb	CMFD
>D>	@		20MG	A206238	006	Nov 19, 2018	Feb	CMFD
>A>	AB		20MG	A206238	006	Nov 19, 2018	Feb	CMFD

TABLET;ORAL
OLANZAPINE

AB	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Jan	CMFD
AB		5MG	A091434	002	Apr 23, 2012	Jan	CMFD
AB		7.5MG	A091434	003	Apr 23, 2012	Jan	CMFD
AB		10MG	A091434	004	Apr 23, 2012	Jan	CMFD
AB		15MG	A091434	005	Apr 23, 2012	Jan	CMFD
AB		20MG	A091434	006	Apr 23, 2012	Jan	CMFD

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL
PRILOSEC

>A>	+	AZURITY	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Feb	CAHN
>A>	+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Feb	CAHN
>D>	+	COVIS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Feb	CAHN
>D>	+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Feb	CAHN

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL
ONDANSETRON HYDROCHLORIDE

>D>	@	PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb	CMFD
>A>	AA		EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb	CMFD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB	UPSHER SMITH LABS	EQ 30MG BASE	A213437	001	Jan 22, 2026	Jan	NEWA
AB		EQ 45MG BASE	A213437	002	Jan 22, 2026	Jan	NEWA
AB		EQ 75MG BASE	A213437	003	Jan 22, 2026	Jan	NEWA

OXALIPLATIN

INJECTABLE;INTRAVENOUS
OXALIPLATIN

AP	SHANDONG	50MG/10ML (5MG/ML)	A219765	001	Jan 15, 2026	Jan	NEWA
AP		100MG/20ML (5MG/ML)	A219765	002	Jan 15, 2026	Jan	NEWA

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

>A>	AB	STERANCO HLTHCARE	300MG/5ML	A220281	001	Mar 09, 2026	Feb	NEWA
-----	----	-------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL
OXCARBAZEPINE

>A>	AB	EPIC PHARMA LLC	150MG	A219556	001	Mar 02, 2026	Feb	NEWA
>A>	AB		300MG	A219556	002	Mar 02, 2026	Feb	NEWA
>A>	AB		600MG	A219556	003	Mar 02, 2026	Feb	NEWA

OXYBUTYNIN CHLORIDE

TABLET;ORAL
OXYBUTYNIN CHLORIDE

AB	!	NOVITIUM PHARMA	5MG	A209823	001	Oct 23, 2017	Jan	CHRS
>D>	!	RISING	2.5MG	A209025	002	Feb 07, 2023	Feb	CTEC
>A>	AB	!	2.5MG	A209025	002	Feb 07, 2023	Feb	CTEC
>A>	AB	STRIDES PHARMA INTL	2.5MG	A075079	002	Mar 10, 2026	Feb	NEWA
AB			5MG	A075079	001	Oct 31, 1997	Jan	CHRS

TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Jan	CHRS
AB	!	ZYDUS PHARMS	15MG	A202332	003	Jun 26, 2017	Jan	CHRS

OZENOXACIN

CREAM;TOPICAL
XEPI

@	+	LNHC	1%	N208945	001	Dec 11, 2017	Jan	CAHN
---	---	------	----	---------	-----	--------------	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL
PALIPERIDONE

AB		APOTEX	3MG	A203279	001	Jan 26, 2026	Jan	NEWA
AB			6MG	A203279	002	Jan 26, 2026	Jan	NEWA
AB			9MG	A203279	003	Jan 26, 2026	Jan	NEWA
	@	RK PHARMA	1.5MG	A203802	001	Sep 24, 2015	Jan	DISC
	@		3MG	A203802	002	Sep 24, 2015	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL
PALIPERIDONE

@		6MG	A203802	003	Sep 24, 2015	Jan DISC
@		9MG	A203802	004	Sep 24, 2015	Jan DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA HAFYERA

+!	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Jan CHRS
+!		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Jan CHRS

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS
PANTOPRAZOLE SODIUM

@	PHARMOBEDIENT	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Jan CAHN
---	---------------	-------------------	---------	-----	--------------	----------

PARICALCITOL

SOLUTION;INTRAVENOUS
PARICALCITOL

@	EUGIA PHARMA	0.002MG/ML (0.002MG/ML)	A205982	001	Oct 09, 2018	Jan DISC
@		0.005MG/ML (0.005MG/ML)	A205982	002	Oct 09, 2018	Jan DISC
@		0.01MG/2ML (0.005MG/ML)	A205982	003	Oct 09, 2018	Jan DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL
PAROXETINE HYDROCHLORIDE

>A>	AB	ANNORA PHARMA	EQ 10MG BASE/5ML	A219954	001	Mar 05, 2026	Feb NEWA
>D>		! NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Feb CTEC
>A>	AB	!	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Feb CTEC

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

>A>		@ INGENUS PHARMS LLC	37.5MG	A091451	001	Sep 21, 2012	Feb CAHN
>D>		@ NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012	Feb CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
PHENYLEPHRINE HYDROCHLORIDE

AP1		HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Jan CMFD
AP1			50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Jan CMFD
AP1			100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Jan CMFD

PHYTONADIONE

INJECTABLE;INJECTION
PHYTONADIONE

>A>	AB	BAXTER HLTHCARE CORP	1MG/0.5ML	A216852	001	Feb 26, 2026	Feb NEWA
	AB1	SUNNY	10MG/ML	A215090	001	Jan 09, 2026	Jan NEWA

TABLET;ORAL
PHYTONADIONE

>A>	AB	SINOTHERAPEUTICS INC	5MG	A220454	001	Feb 26, 2026	Feb NEWA
-----	----	----------------------	-----	---------	-----	--------------	----------

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL
PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	5MG	A212377	001	Aug 13, 2019	Jan CAHN
AB			7.5MG	A212377	002	Aug 13, 2019	Jan CAHN

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL
PIVYA

+!	ALEMBIC THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Jan CAHN
----	----------------	---------------	---------	-----	--------------	----------

PODOFILOX

GEL;TOPICAL
CONDYLOX

@ +	ALLERGAN	0.5%	N020529	001	Mar 13, 1997	Jan DISC
!	PADAGIS US	0.5%	A211871	001	Nov 22, 2023	Jan CHRS
		0.5%	A211871	001	Nov 22, 2023	Jan CTEC

SOLUTION;TOPICAL
CONDYLOX

>D>	AT	+!	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Feb	CAHN
>A>	AT	+!		0.5%	N019795	001	Dec 13, 1990	Feb	CAHN

POMALIDOMIDE

CAPSULE;ORAL
POMALIDOMIDE

AB			APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	CMFD
AB				2MG	A210164	002	Jun 11, 2024	Jan	CMFD
AB				3MG	A210164	003	Jun 11, 2024	Jan	CMFD
AB				4MG	A210164	004	Jun 11, 2024	Jan	CMFD
AB			BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Jan	CMFD
AB				2MG	A210111	002	Oct 30, 2020	Jan	CMFD
AB				3MG	A210111	003	Oct 30, 2020	Jan	CMFD
AB				4MG	A210111	004	Oct 30, 2020	Jan	CMFD
AB			EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Jan	CMFD
AB				2MG	A210249	002	Oct 30, 2020	Jan	CMFD
AB				3MG	A210249	003	Oct 30, 2020	Jan	CMFD
AB				4MG	A210249	004	Oct 30, 2020	Jan	CMFD
AB			HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Jan	CMFD
AB				2MG	A210236	002	Sep 26, 2024	Jan	CMFD
AB				3MG	A210236	003	Sep 26, 2024	Jan	CMFD
AB				4MG	A210236	004	Sep 26, 2024	Jan	CMFD
AB			TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Jan	CMFD
AB				2MG	A209956	002	May 04, 2022	Jan	CMFD
AB				3MG	A209956	003	May 04, 2022	Jan	CMFD
AB				4MG	A209956	004	May 04, 2022	Jan	CMFD

POMALYST

AB		+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan	CTEC
AB		+		2MG	N204026	002	Feb 08, 2013	Jan	CTEC
AB		+		3MG	N204026	003	Feb 08, 2013	Jan	CTEC
AB		+		4MG	N204026	004	Feb 08, 2013	Jan	CTEC

PONATINIB HYDROCHLORIDE

TABLET;ORAL
ICLUSIG

		+	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	Jan	CHRS
		+		EQ 45MG BASE	N203469	002	Dec 14, 2012	Jan	CHRS

POSACONAZOLE

SOLUTION;INTRAVENOUS
NOXAFIL

		@	+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Jan	DISC
AP		!		GLAND	300MG/16.7ML (18MG/ML)	A217553	001	Dec 26, 2023	Jan	CHRS

POTASSIUM ACETATE

INJECTABLE;INJECTION
POTASSIUM ACETATE

		@		EXELA PHARMA	2MEQ/ML	A206203	001	Dec 29, 2015	Jan	DISC
--	--	---	--	--------------	---------	---------	-----	--------------	-----	------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

		@		SENORES PHARMS	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan	CAHN
		@			EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan	CAHN

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

>D>	AB			APNAR PHARMA LP	10MG	A077491	002	Oct 23, 2006	Feb	CAHN
>D>	AB				20MG	A077491	003	Oct 23, 2006	Feb	CAHN
>D>	AB				40MG	A077491	004	Oct 23, 2006	Feb	CAHN
>D>	AB				80MG	A077491	001	Feb 11, 2008	Feb	CAHN
>A>	AB			SENORES PHARMS	10MG	A077491	002	Oct 23, 2006	Feb	CAHN
>A>	AB				20MG	A077491	003	Oct 23, 2006	Feb	CAHN
>A>	AB				40MG	A077491	004	Oct 23, 2006	Feb	CAHN
>A>	AB				80MG	A077491	001	Feb 11, 2008	Feb	CAHN

PREGABALIN

CAPSULE;ORAL
PREGABALIN

>A>	AB	FOURRTS LABS	25MG	A218529	001	Feb 24, 2026	Feb	NEWA
>A>	AB		50MG	A218529	002	Feb 24, 2026	Feb	NEWA
>A>	AB		75MG	A218529	003	Feb 24, 2026	Feb	NEWA
>A>	AB		100MG	A218529	004	Feb 24, 2026	Feb	NEWA
>A>	AB		150MG	A218529	005	Feb 24, 2026	Feb	NEWA
>A>	AB		200MG	A218529	006	Feb 24, 2026	Feb	NEWA
>A>	AB		225MG	A218529	007	Feb 24, 2026	Feb	NEWA
>A>	AB		300MG	A218529	008	Feb 24, 2026	Feb	NEWA
>A>	AB	RENATA	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
>A>	AB		75MG	A210585	002	Dec 26, 2019	Feb	CAHN
>A>	AB		100MG	A210585	003	Dec 26, 2019	Feb	CAHN
>A>	AB		150MG	A210585	004	Dec 26, 2019	Feb	CAHN
>A>	AB		200MG	A210585	005	Dec 26, 2019	Feb	CAHN
>A>	AB		300MG	A210585	006	Dec 26, 2019	Feb	CAHN
>D>	AB	SOMERSET THERAPS LLC	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
>D>	AB		75MG	A210585	002	Dec 26, 2019	Feb	CAHN
>D>	AB		100MG	A210585	003	Dec 26, 2019	Feb	CAHN
>D>	AB		150MG	A210585	004	Dec 26, 2019	Feb	CAHN
>D>	AB		200MG	A210585	005	Dec 26, 2019	Feb	CAHN
>D>	AB		300MG	A210585	006	Dec 26, 2019	Feb	CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

>A>	AB	INGENUS PHARMS LLC	EQ 15MG BASE	A206043	001	Jun 23, 2016	Feb	CAHN
>D>	AB	NOVAST LABS	EQ 15MG BASE	A206043	001	Jun 23, 2016	Feb	CAHN

PRIMIDONE

TABLET;ORAL
PRIMIDONE

>A>	AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Feb	CAHN
>A>	AB		250MG	A218366	002	Jan 23, 2024	Feb	CAHN
>D>	AB	PHARMOBEDIENT	50MG	A218366	001	Jan 23, 2024	Feb	CAHN
>D>	AB		250MG	A218366	002	Jan 23, 2024	Feb	CAHN

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	!	GLAND	100MG/ML	A218135	001	Jul 22, 2024	Jan	CHRS
AP	!		500MG/ML	A218135	002	Jul 22, 2024	Jan	CHRS
AP		HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jan	CHRS
	@		500MG/ML	A089070	001	Feb 12, 1986	Jan	DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

>D>	AP	AMNEAL	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Feb	DISC
>A>		@	EQ 5MG BASE/ML	A214192	001	Nov 28, 2022	Feb	DISC

PROPRANOLOL HYDROCHLORIDE

SOLUTION;ORAL
PROPRANOLOL HYDROCHLORIDE

>A>		!	HIKMA	20MG/5ML	A070690	002	May 15, 1987	Feb	CMS1
-----	--	---	-------	----------	---------	-----	--------------	-----	------

TABLET;ORAL
PROPRANOLOL HYDROCHLORIDE

AB		MANKIND PHARMA	10MG	A216663	001	Jan 27, 2026	Jan	NEWA
AB			20MG	A216663	002	Jan 27, 2026	Jan	NEWA
AB			40MG	A216663	003	Jan 27, 2026	Jan	NEWA
AB			60MG	A216663	004	Jan 27, 2026	Jan	NEWA
AB			80MG	A216663	005	Jan 27, 2026	Jan	NEWA

PRUCALOPRIDE SUCCINATE

TABLET;ORAL
PRUCALOPRIDE SUCCINATE

AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219220	001	Jan 16, 2026	Jan	NEWA
AB			EQ 2MG BASE	A219220	002	Jan 16, 2026	Jan	NEWA
AB		TEVA PHARMS INC	EQ 1MG BASE	A219071	001	Feb 05, 2026	Jan	NEWA
AB			EQ 2MG BASE	A219071	002	Feb 05, 2026	Jan	NEWA

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

@ IMPAX LABS INC 180MG A203184 001 Sep 15, 2015 Jan DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

AB AUROBINDO PHARMA USA 20MG A205761 001 Feb 17, 2017 Jan CAHN

RAMELTEON

TABLET;ORAL
RAMELTEON

>D> BX AUROBINDO PHARMA LTD 8MG A215972 001 Jul 10, 2023 Feb CTEC
>A> AB 8MG A215972 001 Jul 10, 2023 Feb CTEC

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

AB SENORES PHARMS 1.25MG A078191 001 Jun 18, 2008 Jan CAHN
AB 2.5MG A078191 002 Jun 18, 2008 Jan CAHN
AB 5MG A078191 003 Jun 18, 2008 Jan CAHN
AB 10MG A078191 004 Jun 18, 2008 Jan CAHN

SOLUTION;ORAL
VOSTALLY

>D> +! ROSEMONT PHARMS 1MG/ML N219757 001 Jul 23, 2025 Feb CAHN
>A> +! 1MG/ML N219757 001 Jul 23, 2025 Feb CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

>D> @ PIRAMAL 500MG A213085 001 Jul 25, 2023 Feb CMFD
>A> AB 500MG A213085 001 Jul 25, 2023 Feb CMFD
>D> @ 1GM A213085 002 Jul 25, 2023 Feb CMFD
>A> AB 1GM A213085 002 Jul 25, 2023 Feb CMFD

REGADENOSON

SOLUTION;INTRAVENOUS
REGADENOSON

>D> AP GE HEALTHCARE 0.4MG/5ML (0.08MG/ML) A215955 001 Aug 05, 2024 Feb DISC
>A> @ 0.4MG/5ML (0.08MG/ML) A215955 001 Aug 05, 2024 Feb DISC

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL
EDURANT

AB +! JANSSEN PRODS EQ 25MG BASE N202022 001 May 20, 2011 Jan CFTG
AB RILPIVIRINE HYDROCHLORIDE
AB SOMERSET THERAPS LLC EQ 25MG BASE A218798 001 Jan 29, 2026 Jan NFTG

RISPERIDONE

POWDER;INTRAMUSCULAR
RISPERDAL CONSTA

AB +! JANSSEN PHARMS 12.5MG/VIAL N021346 004 Apr 12, 2007 Jan CHRS
AB + 12.5MG/VIAL N021346 004 Apr 12, 2007 Jan CDFR
AB +! 25MG/VIAL N021346 001 Oct 29, 2003 Jan CDFR
AB +! 37.5MG/VIAL N021346 002 Oct 29, 2003 Jan CHRS
AB + 37.5MG/VIAL N021346 002 Oct 29, 2003 Jan CDFR
AB +! 50MG/VIAL N021346 003 Oct 29, 2003 Jan CHRS
AB + 50MG/VIAL N021346 003 Oct 29, 2003 Jan CDFR

RISPERIDONE

AB AMNEAL 12.5MG/VIAL A218586 001 Sep 02, 2025 Jan CDFR
AB 25MG/VIAL A218586 002 Sep 02, 2025 Jan CDFR
AB 37.5MG/VIAL A218586 003 Sep 02, 2025 Jan CDFR
AB 50MG/VIAL A218586 004 Sep 02, 2025 Jan CDFR
AB NANOMI 25MG/VIAL A211220 001 Sep 02, 2025 Jan CDFR
AB 37.5MG/VIAL A211220 002 Sep 02, 2025 Jan CDFR
AB 50MG/VIAL A211220 003 Sep 02, 2025 Jan CDFR
AB TEVA PHARMS USA INC 12.5MG/VIAL A214068 001 Dec 05, 2023 Jan CDFR
AB 25MG/VIAL A214068 002 Dec 05, 2023 Jan CDFR
AB 37.5MG/VIAL A214068 003 Dec 05, 2023 Jan CDFR
AB 50MG/VIAL A214068 004 Dec 05, 2023 Jan CDFR

RITONAVIR

TABLET;ORAL		NORVIR					
AB	+ ABBVIE	100MG	N022417	001	Feb 10, 2010	Jan	CHRS
TABLET;ORAL		RITONAVIR					
AB	! AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Jan	CHRS

RIVAROXABAN

FOR SUSPENSION;ORAL		RIVAROXABAN					
>A>	AB APOTEX	1MG/ML	A218427	001	Mar 02, 2026	Feb	NEWA
TABLET;ORAL		RIVAROXABAN					
>D>	AB BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	Feb	CTEC
>A>	BX	2.5MG	A218107	001	May 14, 2025	Feb	CTEC
>D>	AB	10MG	A218107	002	May 14, 2025	Feb	CTEC
>A>	BX	10MG	A218107	002	May 14, 2025	Feb	CTEC
>D>	AB	15MG	A218107	003	May 14, 2025	Feb	CTEC
>A>	BX	15MG	A218107	003	May 14, 2025	Feb	CTEC
>D>	AB	20MG	A218107	004	May 14, 2025	Feb	CTEC
>A>	BX	20MG	A218107	004	May 14, 2025	Feb	CTEC
>A>	AB INVAGEN PHARMS	2.5MG	A218768	001	Feb 20, 2026	Feb	NEWA

RIZATRIPTAN BENZOATE

FILM;ORAL		RIZAFILM					
>A>	+! GENSCO	EQ 5MG BASE	N205394	002	Feb 26, 2026	Feb	NEWA
TABLET;ORAL		RIZATRIPTAN BENZOATE					
>D>	AB PHARMOBEDIENT	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	DISC
>A>	@	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	DISC
>D>	AB	EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	DISC
>A>	@	EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION		ROCURONIUM BROMIDE					
>A>	AP ASPIRO	50MG/5ML (10MG/ML)	A220124	001	Mar 04, 2026	Feb	NEWA
>A>	AP	100MG/10ML (10MG/ML)	A220124	002	Mar 04, 2026	Feb	NEWA

ROFLUMILAST

TABLET;ORAL		ROFLUMILAST					
>D>	AB PHARMOBEDIENT	500MCG	A208257	001	Jul 13, 2018	Feb	DISC
>A>	@	500MCG	A208257	001	Jul 13, 2018	Feb	DISC
>D>	@ SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb	CMFD
>A>	AB	250MCG	A208236	002	Oct 19, 2023	Feb	CMFD
>D>	@	500MCG	A208236	001	Oct 03, 2018	Feb	CMFD
>A>	AB	500MCG	A208236	001	Oct 03, 2018	Feb	CMFD

SACUBITRIL; VALSARTAN

TABLET;ORAL		SACUBITRIL AND VALSARTAN					
AB	SOMERSET THERAPS LLC	24MG;26MG	A219983	001	Jan 20, 2026	Jan	NEWA
AB		49MG;51MG	A219983	002	Jan 20, 2026	Jan	NEWA
AB		97MG;103MG	A219983	003	Jan 20, 2026	Jan	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL		KUVAN					
AB	+! BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Jan	CHRS
POWDER;ORAL		SAPROPTERIN DIHYDROCHLORIDE					
AB	MICRO LABS	100MG/PACKET	A219511	001	Jan 08, 2026	Jan	NEWA
AB		500MG/PACKET	A219511	002	Jan 08, 2026	Jan	NEWA

SELENIOS ACID

SOLUTION;INTRAVENOUS		SELENIOS ACID					
@	CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jan	DISC
@		EQ 600MCG SELENIUM/10ML (EQ	A218661	002	Jul 21, 2025	Jan	DISC

SOLUTION; INTRAVENOUS
SELENIOS ACID

AP	KINDOS	60MCG SELENIUM/ML) EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219472	001	Feb 03, 2026	Jan NEWA
----	--------	---	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

CAPSULE; ORAL
SERTRALINE HYDROCHLORIDE

AB	APPCO	EQ 150MG BASE	A218712	001	Jan 20, 2026	Jan NEWA
AB		EQ 200MG BASE	A218712	002	Jan 20, 2026	Jan NEWA
AB	NOVITIUM PHARMA	EQ 150MG BASE	A219714	001	Jan 20, 2026	Jan NEWA
AB		EQ 200MG BASE	A219714	002	Jan 20, 2026	Jan NEWA
AB	SKG PHARMA	EQ 150MG BASE	A219655	001	Jan 28, 2026	Jan NEWA
AB		EQ 200MG BASE	A219655	002	Jan 28, 2026	Jan NEWA
AB	UMEDICA	EQ 150MG BASE	A218342	001	Jan 20, 2026	Jan NEWA
AB		EQ 200MG BASE	A218342	002	Jan 20, 2026	Jan NEWA
AB	ZYDUS LIFESCIENCES	EQ 150MG BASE	A220275	001	Jan 29, 2026	Jan NEWA
AB		EQ 200MG BASE	A220275	002	Jan 29, 2026	Jan NEWA

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan CAHN

SIPONIMOD

TABLET; ORAL
MAYZENT

>D>	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Feb CTEC
>A>	AB	+	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Feb CTEC
>D>	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Feb CTEC
>A>	AB	+	EQ 1MG BASE	N209884	003	Aug 24, 2021	Feb CTEC
>D>	+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Feb CTEC
>A>	AB	+	EQ 2MG BASE	N209884	002	Mar 26, 2019	Feb CTEC
		SIPONIMOD					
>A>	AB	AUROBINDO PHARMA LTD	EQ 0.25MG BASE	A218459	001	Mar 06, 2026	Feb NEWA
>A>	AB		EQ 1MG BASE	A218459	002	Mar 06, 2026	Feb NEWA
>A>	AB		EQ 2MG BASE	A218459	003	Mar 06, 2026	Feb NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL
SITAGLIPTIN PHOSPHATE

AB	APOTEX	EQ 25MG BASE	A202425	001	Jan 20, 2026	Jan NEWA
AB		EQ 50MG BASE	A202425	002	Jan 20, 2026	Jan NEWA
AB		EQ 100MG BASE	A202425	003	Jan 20, 2026	Jan NEWA
AB	SANDOZ	EQ 25MG BASE	A202387	001	Jan 14, 2026	Jan NEWA
AB		EQ 50MG BASE	A202387	002	Jan 14, 2026	Jan NEWA
AB		EQ 100MG BASE	A202387	003	Jan 14, 2026	Jan NEWA

SODIUM ACETATE

SOLUTION; INTRAVENOUS
SODIUM ACETATE

>A>	AP	AMNEAL	40MEQ/20ML (2MEQ/ML)	A218469	003	Mar 02, 2026	Feb NEWA
-----	----	--------	----------------------	---------	-----	--------------	----------

SODIUM BICARBONATE

SOLUTION; INTRAVENOUS
SODIUM BICARBONATE

AP	AMNEAL	50MEQ/50ML (1MEQ/ML)	A217523	001	Jan 13, 2026	Jan NEWA
----	--------	----------------------	---------	-----	--------------	----------

SODIUM PHENYL BUTYRATE

POWDER; ORAL
BUPHENYL

@	+	HORIZON THERAP US	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Jan DISC
AB	!	PH HEALTH	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jan CHRS

TABLET; ORAL
BUPHENYL
@ + HORIZON THERAP US
SODIUM PHENYL BUTYRATE

>A>	AB	NAVINTA LLC	500MG	A220418	001	Feb 17, 2026	Feb NEWA
AB	!	PH HEALTH	500MG	A204395	001	Apr 15, 2016	Jan CHRS

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION;INTRAVENOUS
SODIUM PHOSPHATES

>A>	AP	CAPLIN	1.34GM/5ML;1.38GM/5ML (268MG/ML; 276MG/ML)	A220683	001	Feb 23, 2026	Feb	NEWA
>A>	AP		4.02GM/15ML;4.14GM/15ML (268MG/ML; 276MG/ML)	A220683	002	Feb 23, 2026	Feb	NEWA
>A>	AP		13.4GM/50ML;13.8GM/50ML (268MG/ML; 276MG/ML)	A220683	003	Feb 23, 2026	Feb	NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

>D>	@	ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CMFD
>A>	AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CMFD

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL
VYNDAQEL

@ +	FOLDRX PHARMS	20MG		N211996	001	May 03, 2019	Jan	DISC
-----	---------------	------	--	---------	-----	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL
TAPENTADOL HYDROCHLORIDE

	NOVITIUM PHARMA	EQ 20MG BASE/ML		A219119	001	Jan 26, 2026	Jan	NFTG
--	-----------------	-----------------	--	---------	-----	--------------	-----	------

TABLET;ORAL
NUCYNTA

AB	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Jan	CFTG
AB	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Jan	CFTG
AB	+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Jan	CFTG
		TAPENTADOL HYDROCHLORIDE						
AB		HIKMA	EQ 50MG BASE	A205057	001	Feb 10, 2026	Jan	NEWA
AB			EQ 75MG BASE	A205057	002	Feb 10, 2026	Jan	NEWA
AB			EQ 100MG BASE	A205057	003	Feb 10, 2026	Jan	NEWA
AB		HUMANWELL	EQ 50MG BASE	A214378	001	Jan 27, 2026	Jan	NFTG
AB			EQ 75MG BASE	A214378	002	Jan 27, 2026	Jan	NFTG
AB			EQ 100MG BASE	A214378	003	Jan 27, 2026	Jan	NFTG

TAVABOROLE

SOLUTION;TOPICAL
TAVABOROLE

>D>	AB	@	CIPLA	5%	A212224	001	Feb 09, 2021	Jan	DISC
>A>			LUPIN LTD	5%	A212168	001	Feb 08, 2021	Feb	DISC
>A>		@		5%	A212168	001	Feb 08, 2021	Feb	DISC

TAZAROTENE

CREAM;TOPICAL
TAZAROTENE

AB		SOLARIS PHARMA CORP	0.05%	A214560	001	Nov 24, 2025	Jan	CAHN
----	--	---------------------	-------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE;INJECTION
NEUROLITE

>D>		+	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994	Feb	CAHN
>A>		+	SHINE	N/A	N020256	001	Nov 23, 1994	Feb	CAHN

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION
CARDIOLITE

>D>	AP	+	LANTHEUS MEDCL	N/A	N019785	001	Dec 21, 1990	Feb	CAHN
>A>	AP	+	SHINE	N/A	N019785	001	Dec 21, 1990	Feb	CAHN
			MIRALUMA						
>D>		@	LANTHEUS MEDCL	N/A	N019785	003	May 23, 1997	Feb	CAHN
>A>		@	SHINE	N/A	N019785	003	May 23, 1997	Feb	CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS
TECHNELITE

>D>	+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb CAHN
>D>	@		0.0083-2.7 CI/GENERATOR	N017771	001		Feb CAHN
>A>	+	SHINE	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	Feb CAHN
>A>	@		0.0083-2.7 CI/GENERATOR	N017771	001		Feb CAHN

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

AB		AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Jan CMFD
AB			15MG	A203482	002	May 23, 2016	Jan CMFD
AB			22.5MG	A203482	003	May 23, 2016	Jan CMFD
AB			30MG	A203482	004	May 23, 2016	Jan CMFD

TERAZOSIN HYDROCHLORIDECAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

>D>	AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb CAHN
>D>	AB		EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb CAHN
>D>	AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb CAHN
>D>	AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb CAHN
>A>	AB	SENORES PHARMS	EQ 1MG BASE	A074823	001	Mar 30, 1998	Feb CAHN
>A>	AB		EQ 2MG BASE	A074823	002	Mar 30, 1998	Feb CAHN
>A>	AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Feb CAHN
>A>	AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Feb CAHN

TERIFLUNOMIDETABLET; ORAL
TERIFLUNOMIDE

>D>	@	CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Feb CMFD
>A>	AB		7MG	A218663	001	Apr 07, 2025	Feb CMFD
>D>	@		14MG	A218663	002	Apr 07, 2025	Feb CMFD
>A>	AB		14MG	A218663	002	Apr 07, 2025	Feb CMFD

TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

AO		CAPLIN ONE LABS	100MG/ML	A040615	001	Aug 10, 2006	Jan CAHN
AO			200MG/ML	A040615	002	Aug 10, 2006	Jan CAHN

THEOPHYLLINESOLUTION, ELIXIR; ORAL
ELIXOPHYLLIN

@	+	SOLIS PHARMS	80MG/15ML	A085186	001		Jan DISC
	!	PHARM ASSOC	80MG/15ML	A206344	001	Dec 16, 2016	Jan CHRS
			80MG/15ML	A206344	001	Dec 16, 2016	Jan CTEC

THIOTEPAPOWDER; INTRAVENOUS
TEPADINA AND SODIUM CHLORIDE

+	!	ADIENNE SA	400MG	N208264	004	Jan 15, 2026	Jan NEWA
---	---	------------	-------	---------	-----	--------------	----------

TICAGRELORTABLET; ORAL
TICAGRELOR

AB		MANKIND PHARMA	60MG	A217679	001	Feb 06, 2026	Jan NEWA
AB			90MG	A217679	002	Feb 06, 2026	Jan NEWA

TIRZEPATIDESOLUTION; SUBCUTANEOUS
MOUNJARO

+	!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	013	Jan 07, 2026	Jan NEWA
+	!		20MG/2.4ML (8.33MG/ML)	N215866	014	Jan 07, 2026	Jan NEWA
+	!		30MG/2.4ML (12.5MG/ML)	N215866	015	Jan 07, 2026	Jan NEWA
+	!		40MG/2.4ML (16.7MG/ML)	N215866	016	Jan 07, 2026	Jan NEWA
+	!		50MG/2.4ML (20.8MG/ML)	N215866	017	Jan 07, 2026	Jan NEWA
+	!		60MG/2.4ML (25MG/ML)	N215866	018	Jan 07, 2026	Jan NEWA

SOLUTION;SUBCUTANEOUS

MOUNJARO KWIKPEN

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N215866	019	Jan 20, 2026	Jan NEWA
+!		20MG/2.4ML (8.33MG/ML)	N215866	020	Jan 20, 2026	Jan NEWA
+!		30MG/2.4ML (12.5MG/ML)	N215866	021	Jan 20, 2026	Jan NEWA
+!		40MG/2.4ML (16.7MG/ML)	N215866	022	Jan 20, 2026	Jan NEWA
+!		50MG/2.4ML (20.8MG/ML)	N215866	023	Jan 20, 2026	Jan NEWA
+!		60MG/2.4ML (25MG/ML)	N215866	024	Jan 20, 2026	Jan NEWA

ZEPBOUND

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	013	Jan 07, 2026	Jan NEWA
+!		20MG/2.4ML (8.33MG/ML)	N217806	014	Jan 07, 2026	Jan NEWA
+!		30MG/2.4ML (12.5MG/ML)	N217806	015	Jan 07, 2026	Jan NEWA
+!		40MG/2.4ML (16.7MG/ML)	N217806	016	Jan 07, 2026	Jan NEWA
+!		50MG/2.4ML (20.8MG/ML)	N217806	017	Jan 07, 2026	Jan NEWA
+!		60MG/2.4ML (25MG/ML)	N217806	018	Jan 07, 2026	Jan NEWA

ZEPBOUND KWIKPEN

+!	ELI LILLY AND CO	10MG/2.4ML (4.17MG/ML)	N217806	019	Jan 20, 2026	Jan NEWA
+!		20MG/2.4ML (8.33MG/ML)	N217806	020	Jan 20, 2026	Jan NEWA
+!		30MG/2.4ML (12.5MG/ML)	N217806	021	Jan 20, 2026	Jan NEWA
+!		40MG/2.4ML (16.7MG/ML)	N217806	022	Jan 20, 2026	Jan NEWA
+!		50MG/2.4ML (20.8MG/ML)	N217806	023	Jan 20, 2026	Jan NEWA
+!		60MG/2.4ML (25MG/ML)	N217806	024	Jan 20, 2026	Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB	INGENUS PHARMS LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb CAHN
>A>	AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb CAHN
>A>	AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb CAHN
>D>	AB	NOVAST LABS	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb CAHN
>D>	AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb CAHN
>D>	AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb CAHN
	AB	SENORES PHARMS	EQ 4MG BASE	A213365	001	May 13, 2024	Jan CAHN
	AB		EQ 6MG BASE	A213365	002	May 13, 2024	Jan CAHN

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

@	AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Jan DISC
---	-------------------	--------------	---------	-----	--------------	----------

TOLCAPONE

TABLET;ORAL

TOLCAPONE

>A>	AB	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Feb CAHN
>D>	AB	NOVAST LABS	100MG	A208937	001	Aug 07, 2018	Feb CAHN

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB	SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Jan CAHN
AB		25MG	A218642	002	Oct 10, 2024	Jan CAHN
AB	STRIDES PHARMA	50MG	A078418	003	Feb 02, 2026	Jan NEWA

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

AB1	ASCENT PHARMS INC	25MG	A217443	001	Jan 12, 2026	Jan NEWA
AB1		50MG	A217443	002	Jan 12, 2026	Jan NEWA
AB1		100MG	A217443	003	Jan 12, 2026	Jan NEWA
AB1		200MG	A217443	004	Jan 12, 2026	Jan NEWA

TABLET;ORAL

TOPIRAMATE

@	SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	Jan CAHN
@		50MG	A090353	002	Sep 01, 2010	Jan CAHN
@		100MG	A090353	003	Sep 01, 2010	Jan CAHN
@		200MG	A090353	004	Sep 01, 2010	Jan CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

>A>	AP	INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb CAHN
>D>	AP	NOVAST LABS	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Feb CAHN

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

@	SENORES PHARMS	1MG	A 078493	001	Aug 25, 2008	Jan	CAHN
@		2MG	A 078493	002	Aug 25, 2008	Jan	CAHN
@		4MG	A 078493	003	Aug 25, 2008	Jan	CAHN

TRANEXAMIC ACID

TABLET;ORAL

TRANEXAMIC ACID

AB	I 3 PHARMS	650MG	A 219702	001	Jan 26, 2026	Jan	NEWA
----	------------	-------	----------	-----	--------------	-----	------

TRETINOIN

CREAM;TOPICAL

TRETINOIN

AB	ENCUBE	0.1%	A 217833	001	Feb 10, 2026	Jan	NEWA
----	--------	------	----------	-----	--------------	-----	------

TRIAMCINOLONE ACETONIDE

INJECTABLE;INJECTION

KENALOG-10

AB	+! APOTHECON	10MG/ML	N 012041	001		Jan	CHRS
	TRIAMCINOLONE ACETONIDE						
	@ CAPLIN	10MG/ML	A 090166	001	May 27, 2009	Jan	CAHN

TRIAZOLAM

TABLET;ORAL

TRIAZOLAM

>D>	AB	BRECKENRIDGE	0.125MG	A 216890	001	Nov 08, 2022	Feb	DISC
>A>		@	0.125MG	A 216890	001	Nov 08, 2022	Feb	DISC
>D>	AB		0.25MG	A 216890	002	Nov 08, 2022	Feb	DISC
>A>		@	0.25MG	A 216890	002	Nov 08, 2022	Feb	DISC
>A>	AB	INGENUS PHARMS LLC	0.125MG	A 214219	001	Oct 20, 2020	Feb	CAHN
>A>	AB		0.25MG	A 214219	002	Oct 20, 2020	Feb	CAHN
>D>	AB	NOVAST LABS	0.125MG	A 214219	001	Oct 20, 2020	Feb	CAHN
>D>	AB		0.25MG	A 214219	002	Oct 20, 2020	Feb	CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

!	RISING	500MG	A 212238	002	Sep 22, 2023	Jan	CHRS
---	--------	-------	----------	-----	--------------	-----	------

TROSPIMUM CHLORIDE

TABLET;ORAL

TROSPIMUM CHLORIDE

AB	ZAMEER PHARMS	20MG	A 215781	001	Feb 16, 2022	Jan	CAHN
----	---------------	------	----------	-----	--------------	-----	------

URSODIOL

CAPSULE;ORAL

URSODIOL

	STRIDES PHARMA	150MG	A 210344	002	Jan 16, 2026	Jan	NFTG
--	----------------	-------	----------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

>D>	AB	HETERO LABS LTD V	EQ 1GM BASE	A 203047	002	Apr 08, 2015	Feb	CHRS
>A>	AB	!	EQ 1GM BASE	A 203047	002	Apr 08, 2015	Feb	CHRS
		VALTREX						
>D>	AB	+! GLAXOSMITHKLINE	EQ 1GM BASE	N 020487	002	Jun 23, 1995	Feb	CHRS
>A>	AB	+	EQ 1GM BASE	N 020487	002	Jun 23, 1995	Feb	CHRS

VALSARTAN

TABLET;ORAL

VALSARTAN

>A>	@	RENATA	40MG	A 218169	001	Aug 05, 2024	Feb	CAHN
>A>	@		80MG	A 218169	002	Aug 05, 2024	Feb	CAHN
>A>	@		160MG	A 218169	003	Aug 05, 2024	Feb	CAHN
>A>	@		320MG	A 218169	004	Aug 05, 2024	Feb	CAHN
>D>	@	SOMERSET THERAPS LLC	40MG	A 218169	001	Aug 05, 2024	Feb	CAHN
>D>	@		80MG	A 218169	002	Aug 05, 2024	Feb	CAHN
>D>	@		160MG	A 218169	003	Aug 05, 2024	Feb	CAHN
>D>	@		320MG	A 218169	004	Aug 05, 2024	Feb	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

>A>	AP	EUROFARMA	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb CAHN
>D>	AP	MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb CAHN

POWDER; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

!	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan CHRS
		EQ 100GM BASE	A091532	001	Jan 06, 2016	Jan CTNA

VARENICLINE TARTRATE

TABLET; ORAL
VARENICLINE TARTRATE

AB		PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jan CMFD
AB			EQ 1MG BASE	A217115	002	Jul 23, 2024	Jan CMFD
AB		UMEDICA	EQ 0.5MG BASE	A218985	001	Jan 09, 2026	Jan NEWA
AB			EQ 1MG BASE	A218985	002	Jan 09, 2026	Jan NEWA

VIGABATRIN

FOR SOLUTION; ORAL
VIGABATRIN

@	TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Jan DISC
---	-----------------	--------------	---------	-----	--------------	----------

XENON XE-133

GAS; INHALATION
XENON XE 133

>D>		LANTHEUS MEDCL	10mCi/VIAL	N017284	001		Feb CAHN
>D>			20mCi/VIAL	N017284	002		Feb CAHN
>A>		SHINE	10mCi/VIAL	N017284	001		Feb CAHN
>A>			20mCi/VIAL	N017284	002		Feb CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP		GLAND	EQ 4MG BASE/100ML	A219984	001	Feb 05, 2026	Jan NEWA
	@	HOSPIRA INC	EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Jan DISC

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

@	SENORES PHARMS	5MG	A077985	001	Apr 23, 2007	Jan CAHN
@		10MG	A077985	002	Apr 23, 2007	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL
ZOLPIDEM TARTRATE

AB		BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Jan CMFD
AB			12.5MG	A213592	002	Jun 04, 2020	Jan CMFD

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
AZELASTINE HYDROCHLORIDE

>D>	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	Feb DISC
>A>	@	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

>A>	DYNA-HEX 2					
>A>	+! XTTRIUM	2%	N019422	001	Dec 17, 1985	Feb CTNA
>A>	DYNA-HEX 4					
>A>	XTTRIUM	4%	N019125	001	Dec 24, 1984	Feb CTNA
>D>	EXIDINE					
>D>	+! XTTRIUM	2%	N019422	001	Dec 17, 1985	Feb CTNA
>D>		4%	N019125	001	Dec 24, 1984	Feb CTNA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	@ AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Feb CMFD
>A>		180MG;240MG	A215232	001	Apr 17, 2025	Feb CMFD

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

>A>	RUBICON RESEARCH	100MG/5ML	A220239	001	Mar 05, 2026	Feb NEWA
-----	------------------	-----------	---------	-----	--------------	----------

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

>A>	INSTAPILL	5MG	A212795	001	Sep 18, 2020	Feb CAHN
>A>		10MG	A213294	001	Oct 30, 2020	Feb CAHN
>D>	TENSHI	5MG	A212795	001	Sep 18, 2020	Feb CAHN
>D>		10MG	A213294	001	Oct 30, 2020	Feb CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>D>	FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Feb DISC
>A>	@	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Feb DISC

PERMETHRIN

LOTION;TOPICAL

PERMETHRIN

>D>	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001	Feb DISC
>A>	@	1%	A076090	001	Dec 20, 2001	Feb DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2026

NO FEBRUARY 2026 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2026 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11207311	Jul 28, 2037	U-2830		I-980	Dec 12, 2028
	11207311	Jul 28, 2037	U-4368			
	11673877	Mar 27, 2038	DS DP U-2830			
	11673877	Mar 27, 2038	DS DP U-4368			
	11986468	Jul 28, 2037	U-2830			
	11986468	Jul 28, 2037	U-4368			
	11986469	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-4368			
	11986470	Jul 28, 2037	U-4368			
	11992486	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-4368			
	12383543	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-4368			
	8071579	Aug 12, 2027	U-2830			
	8071579	Aug 12, 2027	U-4368			
	8143241	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-4368			
	8859562	Aug 04, 2031	U-2830			
	8859562	Aug 04, 2031	U-4368			
<u>ACECLIDINE HYDROCHLORIDE - VIZZ</u>						
N 218585 001 >A>	12533347	Oct 08, 2039	U-3741			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001 >A>	12539290	Aug 16, 2039	DP			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 001	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 002	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 003	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 004	10836755	Jan 18, 2039	DS DP U-4371			
	12370179	Jul 15, 2042	U-4371			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Apr 10, 2030	DS			
<u>ARTICAINE HYDROCHLORIDE - CYKLX</u>						
N 218643 001	>A> 11096922	Mar 27, 2039	DP U-4423			
	>A> 11826347	Mar 27, 2039	DP U-4423			
	>A> 12403126	Mar 27, 2039	DP U-4422			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	12521369	Feb 23, 2041	U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2027	DS			
	9617546	Feb 14, 2027	DS U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	8906938	Jan 06, 2034	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	12509450	Dec 29, 2042	DP			
<u>AXITINIB - INLYTA</u>						
N 202324 001	>A> 12534530	Feb 03, 2035	U-4411			
	>A> 12534530	Feb 03, 2035	U-4412			
	>A> 12534530*PED	Aug 03, 2035				
<u>AXITINIB - INLYTA</u>						
N 202324 002	>A> 12534530	Feb 03, 2035	U-4411			
	>A> 12534530	Feb 03, 2035	U-4412			
	>A> 12534530*PED	Aug 03, 2035				
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	8987441	Oct 24, 2032	DS DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	8987441	Oct 24, 2032	DS DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	>A> 12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	>A> 12551491	Jul 23, 2045	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	>A> 12551491	Jul 23, 2045	U-713			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 002	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 004	>A> 12545645	Nov 01, 2039	DS DP			
	>A> 12545646	Nov 01, 2039	DS DP			
	>A> 12545647	Nov 01, 2039	DS DP			
	>A> 12552750	Nov 01, 2039	DS DP			
<u>BRIMONIDINE TARTRATE; CARBACHOL - YUVEZZI</u>						
N 220142 001	>A> 12268662	Nov 10, 2042	DP U-3741		>A> NP	Jan 28, 2029
	>A> 12268662	Nov 10, 2042	DP U-4419			
	>A> 12268662	Nov 10, 2042	DP U-4420			
	>A> 8455494	May 24, 2030	U-3741			
	>A> 8455494	May 24, 2030	U-4419			
	>A> 8455494	May 24, 2030	U-4420			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10583110*PED	Apr 27, 2031				
	10716777	Oct 27, 2030	U-2856			
	10716777*PED	Apr 27, 2031				
	12453712	Oct 27, 2030	U-4334			
	12453712*PED	Apr 27, 2031				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> 7737142	Sep 17, 2029	DS DP U-1750			
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142	Sep 17, 2029	DS DP U-2545			
	>A> 7737142	Sep 17, 2029	DS DP U-3503			
	>A> 7737142*PED	Mar 17, 2030				
	>A> 7943621	Dec 16, 2028	DS DP			
	>A> 7943621*PED	Jun 16, 2029				
	>A> RE47350	Jul 16, 2029	U-1750			
	>A> RE47350	Jul 16, 2029	U-2543			
	>A> RE47350	Jul 16, 2029	U-2544			
	>A> RE47350	Jul 16, 2029	U-2545			
	>A> RE47350	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	>A> RE47350*PED	Jan 16, 2030				
	>A> RE49110	Jul 16, 2029	U-2543			
	>A> RE49110	Jul 16, 2029	U-2544			
	>A> RE49110	Jul 16, 2029	U-2545			
	>A> RE49110	Jul 16, 2029	U-3503			
	>A> RE49110*PED	Jan 16, 2030				
	>A> RE49302	Jul 16, 2029	U-2543			
	>A> RE49302	Jul 16, 2029	U-2544			
	>A> RE49302	Jul 16, 2029	U-2545			
	>A> RE49302	Jul 16, 2029	U-3503			
	>A> RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	>A> 7737142	Sep 17, 2029	DS DP U-1750			
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142	Sep 17, 2029	DS DP U-2545			
	>A> 7737142	Sep 17, 2029	DS DP U-3503			
	>A> 7737142*PED	Mar 17, 2030				
	>A> 7943621	Dec 16, 2028	DS DP			
	>A> 7943621*PED	Jun 16, 2029				
	>A> RE49110	Jul 16, 2029	U-2543			
	>A> RE49110	Jul 16, 2029	U-2544			
	>A> RE49110	Jul 16, 2029	U-2545			
	>A> RE49110	Jul 16, 2029	U-3503			
	>A> RE49110*PED	Jan 16, 2030				
	>A> RE49302	Jul 16, 2029	U-2543			
	>A> RE49302	Jul 16, 2029	U-2544			
	>A> RE49302	Jul 16, 2029	U-2545			
	>A> RE49302	Jul 16, 2029	U-3503			
	>A> RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	>A> 7737142	Sep 17, 2029	DS DP U-1750			
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142*PED	Mar 17, 2030				
	>A> 7943621	Dec 16, 2028	DS DP			
	>A> 7943621*PED	Jun 16, 2029				
	>A> RE49110	Jul 16, 2029	U-2543			
	>A> RE49110	Jul 16, 2029	U-2544			
	>A> RE49110	Jul 16, 2029	U-2545			
	>A> RE49110*PED	Jan 16, 2030				
	>A> RE49302	Jul 16, 2029	U-2543			
	>A> RE49302	Jul 16, 2029	U-2544			
	>A> RE49302	Jul 16, 2029	U-2545			
	>A> RE49302	Jul 16, 2029	U-3503			
	>A> RE49302*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	>A> 7737142	Sep 17, 2029	DS DP U-1750			
	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142*PED	Mar 17, 2030				
	>A> 7943621	Dec 16, 2028	DS DP			
	>A> 7943621*PED	Jun 16, 2029				
	>A> RE49110	Jul 16, 2029	U-2543			
	>A> RE49110	Jul 16, 2029	U-2544			
	>A> RE49110	Jul 16, 2029	U-2545			
	>A> RE49110*PED	Jan 16, 2030				
	>A> RE49302	Jul 16, 2029	U-2543			
	>A> RE49302	Jul 16, 2029	U-2544			
	>A> RE49302	Jul 16, 2029	U-2545			
	>A> RE49302	Jul 16, 2029	U-3503			
	>A> RE49302*PED	Jan 16, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 005	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142	Sep 17, 2029	DS DP U-2545			
	>A> 7737142	Sep 17, 2029	DS DP U-3503			
	>A> 7737142*PED	Mar 17, 2030				
	>A> 7943621	Dec 20, 2028	DS DP			
	>A> 7943621*PED	Jun 20, 2029				
	>A> RE47350	Jul 16, 2029		U-2543		
	>A> RE47350	Jul 16, 2029		U-2544		
	>A> RE47350	Jul 16, 2029		U-2545		
	>A> RE47350	Jul 16, 2029		U-3503		
	>A> RE47350*PED	Jan 16, 2030				
	>A> RE49110	Jul 16, 2029		U-2543		
	>A> RE49110	Jul 16, 2029		U-2544		
	>A> RE49110	Jul 16, 2029		U-2545		
	>A> RE49110	Jul 16, 2029		U-3503		
	>A> RE49110*PED	Jan 16, 2030				
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 006	>A> 7737142	Sep 17, 2029	DS DP U-2543			
	>A> 7737142	Sep 17, 2029	DS DP U-2544			
	>A> 7737142	Sep 17, 2029	DS DP U-2545			
	>A> 7737142	Sep 17, 2029	DS DP U-3503			
	>A> 7737142*PED	Mar 17, 2030				
	>A> 7943621	Dec 20, 2028	DS DP			
	>A> 7943621*PED	Jun 20, 2029				
	>A> RE47350	Jul 16, 2029		U-2543		
	>A> RE47350	Jul 16, 2029		U-2544		
	>A> RE47350	Jul 16, 2029		U-2545		
	>A> RE47350	Jul 16, 2029		U-3503		
	>A> RE47350*PED	Jan 16, 2030				
	>A> RE49110	Jul 16, 2029		U-2543		
	>A> RE49110	Jul 16, 2029		U-2544		
	>A> RE49110	Jul 16, 2029		U-2545		
	>A> RE49110	Jul 16, 2029		U-3503		
	>A> RE49110*PED	Jan 16, 2030				
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	12533408	Sep 10, 2041		U-4395		
	12539329	Sep 10, 2041		U-4399		
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	>A> 11179465	Aug 31, 2030	DP U-1858			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12514819	Nov 22, 2036		U-2814		
<u>COPPER HISTIDINATE - ZYCUBO</u>						
N 211241 001					NCE	Jan 12, 2031
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				
	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032		U-3150		
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029		U-3147		
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150		PED	Sep 30, 2028
	10028912*PED	Apr 15, 2033				
	10166184	Oct 15, 2032	DP U-3149			
	10166184*PED	Apr 15, 2033				
	10835492	Oct 15, 2032	U-3150			
	10835492*PED	Apr 15, 2033				
	7850990	Jan 23, 2027	DP U-3147			
	7850990*PED	Jul 23, 2027				
	8022279	Sep 14, 2027	DP U-3147			
	8022279*PED	Mar 14, 2028				
	8092828	Apr 01, 2029	U-3147			
	8092828*PED	Oct 01, 2029				
	9271931	Jan 23, 2027	DP			
	9271931*PED	Jul 23, 2027				
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	12329742	Jun 17, 2042	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 001	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 002	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 003	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 004	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 005	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	>A> 12544376	Jan 22, 2041	U-3767			
	>A> 12544376	Jan 22, 2041	U-3768			
	>A> 12544376	Jan 22, 2041	U-3769			
	>A> 12544376	Jan 22, 2041	U-3770			
	>A> 12544376	Jan 22, 2041	U-3771			
	>A> 12544376	Jan 22, 2041	U-3772			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	>A> 12529052	Jun 22, 2032	DP			
	>A> 12534722	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	12514898	Feb 20, 2029	U-1978			
	>A> 12533387	Feb 20, 2029	U-4417			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	12514898	Feb 20, 2029	U-1978			
	>A> 12533387	Feb 20, 2029	U-4417			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001	12521390	Feb 11, 2043	DP U-3434			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12521400	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12521400	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12521400	Mar 27, 2029	DP			
<u>DIFAMILAST - ADOUEY</u>						
N 219474 001					>A> NCE	Feb 12, 2031
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	>A> 12533351	Feb 26, 2039	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12527769	Nov 12, 2041	U-4111			
<u>ELAMIPRETIDE HYDROCHLORIDE - FORZINITY</u>						
N 215244 001	7576061	Jan 20, 2027	DS DP			
<u>ELINZANETANT - LYNKUET</u>						
N 219469 001	12533358	May 14, 2045	U-4402			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 12527810	Apr 22, 2033	U-4403			
	>A> 12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 12527810	Apr 22, 2033	U-4403			
	>A> 12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 12527810	Apr 22, 2033	U-4403			
	>A> 12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 12527810	Apr 22, 2033	U-4403			
	>A> 12527810*PED	Oct 22, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 12527810	Apr 22, 2033	U-4403			
	>A> 12527810*PED	Oct 22, 2033				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 12527810	Apr 22, 2033	U-4403			
	>A> 12527810*PED	Oct 22, 2033				
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 215425 001	12539283	Jan 17, 2045	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	>A> 12551447	Nov 05, 2042	DP			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002					>A> D-199	Jan 16, 2029
<u>ETRIPAMIL - CARDAMYST</u>						
N 218571 001	10010522	Jun 19, 2028	U-38			
	10010523	Jun 19, 2028	DS			
	10117848	Apr 13, 2036	DP U-4370			
	12257224	Jul 15, 2042	U-4370			
	9227918	Jun 19, 2028	DP			
	9463179	Jun 19, 2028	U-4370			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2027	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2027	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 001	8436180	Aug 26, 2033	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	8436180	Aug 26, 2033	DS DP			
<u>FINERENONE - KERENDIA</u>						
N 215341 003	8436180	Aug 26, 2033	DS DP			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001					>A> I-983	Dec 13, 2028
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168 001	12527884	May 13, 2042	DP U-4406			
<u>FOSFOMYCIN DISODIUM - CONTEPO</u>						
N 212271 001					NP GAIN	Oct 22, 2028 Oct 22, 2033
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	>A> 12064487	Jan 17, 2040	U-4424			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	>A> 12064487	Jan 17, 2040	U-4424			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	>A> 12064487	Jan 17, 2040	U-4424			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	>A> 12064487	Jan 17, 2040	U-4424			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	>A> 12064487	Jan 17, 2040	U-4424			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	>A> 12064487	Jan 17, 2040	U-4424			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	>A> 8318714	Nov 28, 2031	DP			
<u>GEPOTIDACIN MESYLATE - BLUJEP A</u>						
N 218230 001	>A> 12528809	Dec 13, 2042	DS DP U-4361			
	>A> 12528809	Dec 13, 2042	DS DP U-4408			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	7329689	Jan 15, 2027	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	8148401	Apr 14, 2029	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	8148401	Apr 14, 2029	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2026	DS DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2026	DS DP			
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	>A> 10125369	Aug 18, 2034	DS DP U-4249		>A> I-985	Feb 12, 2029
	>A> 10125369	Aug 18, 2034	DS DP U-4413		>A> NPP	Feb 12, 2029
	>A> 10125369	Aug 18, 2034	DS DP U-4414			
	>A> 10131907	Aug 24, 2028	DS DP U-4249			
	>A> 10131907	Aug 24, 2028	DS DP U-4413			
	>A> 10131907	Aug 24, 2028	DS DP U-4414			
	>A> 10851377	Aug 25, 2036	U-4249			
	>A> 10851377	Aug 25, 2036	U-4413			
	>A> 10851377	Aug 25, 2036	U-4414			
	>A> 8106022	Dec 12, 2029	DS DP U-4249			
	>A> 8106022	Dec 12, 2029	DS DP U-4413			
	>A> 8106022	Dec 12, 2029	DS DP U-4414			
	>A> 8222222	Dec 29, 2027	U-4249			
	>A> 8222222	Dec 29, 2027	U-4413			
	>A> 8222222	Dec 29, 2027	U-4414			
	>A> 8809292	May 10, 2027	DS DP U-4249			
	>A> 8809292	May 10, 2027	DS DP U-4413			
	>A> 8809292	May 10, 2027	DS DP U-4414			
	>A> 8828956	Dec 04, 2028	DS DP U-4249			
	>A> 8828956	Dec 04, 2028	DS DP U-4413			
	>A> 8828956	Dec 04, 2028	DS DP U-4414			
	>A> 9370582	Dec 04, 2028	DS DP U-4249			
	>A> 9370582	Dec 04, 2028	DS DP U-4413			
	>A> 9370582	Dec 04, 2028	DS DP U-4414			
<u>IOHEXOL - IOHEXOL</u>						
A 217737 001					CGT	Jul 26, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETOZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12544380	Aug 07, 2034	U-3264			
	12544380	Aug 07, 2034	U-3998			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 001 >A>	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 002 >A>	12564592	Dec 23, 2044	DP			
<u>LEUCOVORIN CALCIUM - VYKOURA</u>						
N 220406 003 >A>	12564592	Dec 23, 2044	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001 >A>	12558328	Jan 14, 2031	U-4421			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001					NPP PED	Nov 04, 2028 May 04, 2029
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 001					>A> CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 002					>A> CGT	May 19, 2026
<u>LOMUSTINE - LOMUSTINE</u>						
A 219265 003					>A> CGT	May 19, 2026
<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN - LOTEPREDNOL ETABONATE AND TOBRAMYCIN</u>						
A 217597 001					CGT	Jul 14, 2026
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001 >A>	12527771	Oct 11, 2043	DS DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001 >A>	12544383	Mar 10, 2045	U-1719			
	>A> 12551488	May 28, 2040	U-1719			
	>A> 12551489	May 28, 2040	U-1719			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	12533342	May 20, 2039	U-3421			
<u>MITAPIVAT SULFATE - AOVESME</u>						
N 216196 004	10632114	May 03, 2032	U-4391		>A> NCE	Feb 17, 2027
	11254652	Nov 21, 2038	DS DP		>A> NP	Dec 23, 2028
	11878049	Jul 31, 2041	U-4390			
	9193701	Oct 26, 2032	U-4393			
	9682080	May 03, 2032	U-4392			
	RE49582	Feb 24, 2031	DS DP			
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001	12514854	Feb 05, 2041	U-4397			
<u>NAVEPEGITIDE - YUUIWEL</u>						
N 219164 001					>A> ODE-516	Feb 27, 2033
<u>NAVEPEGITIDE - YUUIWEL</u>						
N 219164 002					>A> ODE-516	Feb 27, 2033

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAVEPEGITIDE - YUWIWEL</u>						
N 219164 003					>A> ODE-516	Feb 27, 2033
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 001	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373			
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 002	11406638	Oct 22, 2038	U-4297		I-979	Dec 19, 2028
	11406638	Oct 22, 2038	U-4373			
	11813266	Oct 22, 2038	U-4292			
	11813266	Oct 22, 2038	U-4372			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	>A> 10251848	Feb 26, 2035	DP	Y		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 004	10888534	Apr 26, 2039	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 001					CGT	Aug 02, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 002					CGT	Jul 27, 2026
<u>OCTREOTIDE ACETATE - OCTREOTIDE ACETATE</u>						
A 216589 003					CGT	Jul 27, 2026
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	>A> 12545705	Nov 08, 2031	U-3186			
	>A> 12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	>A> 12545705	Nov 08, 2031	U-3186			
	>A> 12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	>A> 12545705	Nov 08, 2031	U-3186			
	>A> 12545705	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12508234	Jun 20, 2039	U-3186			
	12508234	Jun 20, 2039	U-3648			
	>A> 12545705	Nov 08, 2031	U-3186			
	>A> 12545705	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	May 31, 2033	DP U-3140			
	10300054	May 31, 2033	DP U-3141			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	12509684	May 01, 2034	U-4050			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	12514899	Aug 29, 2029	U-4398			
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	12514899	Aug 29, 2029	U-4398			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7771707	Oct 09, 2028	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7771707	Oct 09, 2028	DP			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	12528836	Oct 07, 2036	U-4394			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					I-981	Dec 02, 2028
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					I-981	Dec 02, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					>A> NPP	Jan 27, 2029
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 9023790	Jul 04, 2031	DP U-1698		>A> NPP	Jan 27, 2029
	>A> 9023790	Jul 04, 2031	DP U-3160			
	>A> 9023790	Jul 04, 2031	DP U-3171			
	>A> 9023790	Jul 04, 2031	DP U-4415			
	>A> 9023790	Jul 04, 2031	DP U-4416			
	>A> 9358297	Jun 24, 2031	DP U-3160			
	>A> 9358297	Jun 24, 2031	DP U-3171			
	>A> 9358297	Jun 24, 2031	DP U-4415			
	>A> 9358297	Jun 24, 2031	DP U-4416			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					>A> I-984	Jan 27, 2029
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 001	12539314	Mar 07, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
N 206814 002	12539314	Mar 07, 2039	DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	>A> 12448366	Jul 07, 2042	DS			
	>A> 12539303	Apr 03, 2039	U-2828			
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	>A> 12544337	Dec 23, 2039	DP U-4026			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12544379	Aug 07, 2034	U-3975			
	12544380	Aug 07, 2034	U-4404			
	12544380	Aug 07, 2034	U-4405			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	12503469	Feb 18, 2034	DP U-2834			
	12503469	Feb 18, 2034	DP U-2835			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001				>A> I-982		Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002				>A> I-982		Dec 17, 2028
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003				>A> I-982		Dec 17, 2028
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 12544381	May 20, 2031	DP			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10821108*PED	Jun 01, 2037				
	10828298	Dec 01, 2036	DP U-2991			
	10828298*PED	Jun 01, 2037				
	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	7205302*PED	Apr 30, 2027				
	8791122	Aug 01, 2030	DS DP			
	8791122*PED	Feb 01, 2031				
	9173881	Aug 12, 2029	U-1798			
	9173881*PED	Feb 12, 2030				
	9284280	Jun 25, 2030	U-1831			
	9284280*PED	Dec 25, 2030				
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001 >A>	9457154	Sep 29, 2027	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	12514822	May 02, 2034	U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005 >A>	12551536	Oct 10, 2038	U-4418			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 001	10278923	May 02, 2034	U-4389		>A> I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		>A> NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 002	10278923	May 02, 2034	U-4389		>A> I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		>A> NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 003	10278923	May 02, 2034	U-4389		>A> I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		>A> NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 218316 004	10278923	May 02, 2034	U-4389		>A> I-935	Mar 08, 2027
	11382957	Dec 16, 2031	DP		>A> NP	Dec 22, 2028
	11833248	Feb 01, 2039	DP U-4387			
	12239739	May 02, 2034	U-4388			
	12396953	Feb 01, 2039	DP U-4387			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9278123	Dec 16, 2031	DP U-4389			
<u>SEVABERTINIB - HYRNUO</u>						
N 219972 001	10428063	Oct 10, 2035	DS DP			
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 001	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 002	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 003	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SILDENAFIL CITRATE - VYBRIQUE</u>						
N 210858 004	11123287	Dec 16, 2033	DP		NP	Dec 16, 2028
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	>A> 12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	>A> 12533340	Apr 23, 2036	U-4407			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	>A> 12533340	Apr 23, 2036	U-4407			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12539299	Nov 26, 2042	DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12539299	Nov 26, 2042	DP			
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 004 >A>	9931458	May 31, 2037	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12343382	Jul 22, 2039	U-4229		>A> NPP	Dec 19, 2028
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	12453755	Jun 14, 2039	U-4375			
	12453755	Jun 14, 2039	U-4376			
	12453755	Jun 14, 2039	U-4377			
	12453755	Jun 14, 2039	U-4378			
	12453755	Jun 14, 2039	U-4379			
	12453755	Jun 14, 2039	U-4380			
	12453755	Jun 14, 2039	U-4381			
	12453755	Jun 14, 2039	U-4382			
	12453755	Jun 14, 2039	U-4383			
	12453755	Jun 14, 2039	U-4384			
	12453755	Jun 14, 2039	U-4385			
	12453755	Jun 14, 2039	U-4386			
	9474780	Jan 05, 2036	DS DP U-4374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 013	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 014	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 015	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 016	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 017	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 018	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
	>A> 12343382	Jul 22, 2039	U-4400			
	>A> 12343382	Jul 22, 2039	U-4401			
	>A> 9474780	Jan 05, 2036	DS DP U-4374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 019	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 020	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 021	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 022	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 023	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12343382	Jul 22, 2039	U-4400			
	12343382	Jul 22, 2039	U-4401			
	9474780	Jan 05, 2036	DS DP U-4374			
<u>TIRZEPATIDE - MOUNJARO KWIKPEN</u>						
N 215866 024	>A> 12295987	Dec 30, 2041	U-4192			
	>A> 12295987	Dec 30, 2041	U-4193			
	>A> 12343382	Jul 22, 2039	U-4229			
	>A> 12343382	Jul 22, 2039	U-4230			
	>A> 12343382	Jul 22, 2039	U-4231			
	>A> 12343382	Jul 22, 2039	U-4232			
	>A> 12343382	Jul 22, 2039	U-4400			
	>A> 12343382	Jul 22, 2039	U-4401			
	>A> 9474780	Jan 05, 2036	DS DP U-4374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 013	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 014	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 015	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 016	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 017	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 018	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 019	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 020	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 021	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 022	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 023	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND KWIKPEN</u>						
N 217806 024	>A> 12343382	Jul 22, 2039	U-4227			
	>A> 12343382	Jul 22, 2039	U-4228			
	>A> 12343382	Jul 22, 2039	U-4409			
	>A> 12343382	Jul 22, 2039	U-4410			
	>A> 12453758	Jul 22, 2039	U-4308			
	>A> 12453758	Jul 22, 2039	U-4309			
	>A> 12453758	Jul 22, 2039	U-4310			
	>A> 12453758	Jul 22, 2039	U-4311			
	>A> 9474780	Jan 05, 2036	DS DP			
<u>TRADIPITANT - NEREUS</u>						
N 220152 001	10772880	Mar 04, 2036	U-4396			
	10821099	Mar 04, 2036	U-4396			
	11324735	Mar 04, 2036	U-4396			
	12318375	Aug 09, 2036	U-4396			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	>A> 7199162	Oct 12, 2026	U-4142			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	>A> 7199162	Oct 12, 2026	U-4142			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	>A> 12551461	Nov 14, 2034	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12527798	Dec 05, 2037	U-3504			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	>A> 11370755	Aug 03, 2040	DS DP		>A> NCE	Mar 10, 2028
	>A> 11370755*PED	Feb 03, 2041			>A> ODE-425	Mar 10, 2030
	>A> 11827600	Jul 12, 2042	DS DP U-3556		>A> PED	Sep 10, 2028
	>A> 11827600*PED	Jan 12, 2043			>A> PED	Sep 10, 2030
	>A> 12492167	Jul 12, 2042	DS DP U-3556			
	>A> 12492167*PED	Jan 12, 2043				
	>A> 9212204	Jan 27, 2032	U-3556			
	>A> 9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 001	>A> 11370755	Aug 03, 2040	DS DP		>A> NCE	Mar 10, 2028
	>A> 11370755*PED	Feb 03, 2041			>A> ODE*	Mar 10, 2030
	>A> 11827600	Jul 12, 2042	DS DP U-3556		>A> PED	Sep 10, 2028
	>A> 11827600*PED	Jan 12, 2043			>A> PED	Sep 10, 2030
	>A> 12492167	Jul 12, 2042	DS DP U-3556			
	>A> 12492167*PED	Jan 12, 2043				
	>A> 9212204	Jan 27, 2032	U-3556			
	>A> 9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 002	>A> 11370755	Aug 03, 2040	DS DP		>A> NCE	Mar 10, 2028
	>A> 11370755*PED	Feb 03, 2041			>A> ODE*	Mar 10, 2030
	>A> 11827600	Jul 12, 2042	DS DP U-3556		>A> PED	Sep 10, 2028
	>A> 11827600*PED	Jan 12, 2043			>A> PED	Sep 10, 2030
	>A> 12492167	Jul 12, 2042	DS DP U-3556			
	>A> 12492167*PED	Jan 12, 2043				
	>A> 9212204	Jan 27, 2032	U-3556			
	>A> 9212204*PED	Jul 27, 2032				
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003	>A> 11370755	Aug 03, 2040	DS DP		>A> NCE	Mar 10, 2028
	>A> 11370755*PED	Feb 03, 2041			>A> ODE*	Mar 10, 2030
	>A> 11827600	Jul 12, 2042	DS DP U-3556		>A> PED	Sep 10, 2028
	>A> 11827600*PED	Jan 12, 2043			>A> PED	Sep 10, 2030
	>A> 12492167	Jul 12, 2042	DS DP U-3556			
	>A> 12492167*PED	Jan 12, 2043				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2026

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003	>A> 9212204	Jan 27, 2032	U-3556			
	>A> 9212204*PED	Jul 27, 2032				
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	>A> 8648087	Jan 14, 2031	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	>A> 8648087	Jan 14, 2031	DS DP			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001					>A> D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002					>A> D-198	Jan 21, 2029
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003					>A> D-198	Jan 21, 2029
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	>A> 12551483	Dec 06, 2044	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	>A> 12551483	Dec 06, 2044	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	12509443	Apr 30, 2045	DP			
	12528787	Dec 06, 2044	DS DP			
	>A> 12551483	Dec 06, 2044	DP			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2027	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001	7977488	Apr 10, 2030	DS			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002	7977488	Apr 10, 2030	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12514906	Aug 01, 2036	DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12514906	Aug 01, 2036	DP U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12514906	Aug 01, 2036	DP U-3927			
<u>ZIFTOMENIB - KOMZIFTI</u>						
N 220305 001	12521396	Jul 16, 2044	DP			
<u>ZOLIFLODACIN - NUZOLVENCE</u>						
N 219491 001	8658641	Jun 20, 2030	DS			
	8889671	Jan 21, 2034	DS		U-4369	
	9040528	Oct 13, 2029			U-4369	
	9187495	Jan 21, 2034	DS		U-4369	
	9540394	Jan 21, 2034			U-4369	
	9839641	Jan 21, 2034			U-4369	

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 46TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm